CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 1  
 
 
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed 
Medications  
 
   
IND Number:  
 155481  
Principal Investigator:  [INVESTIGATOR_88471], MD, MHS  
Duke Clinical Research Institute  
[ADDRESS_552617]. 
Durham, NC [ZIP_CODE] 
Phone: [PHONE_9077] 
Email: [EMAIL_1789]  
Co-Principal 
Investigator /IND 
Sponsor : Susanna Naggie, MD, MHS  
Duke Clinical Research Institute  
[ADDRESS_552618]. 
Durham, NC [ZIP_CODE] 
Phone: [PHONE_9078] 
Email: [EMAIL_1790]  
Data Coordinating 
Center Investigator Chris Lindsell , PhD 
Duke Clinical Research Institute  
[ADDRESS_552619]. 
Durham, NC [ZIP_CODE] 
Phone: [PHONE_9079] 
Email: [EMAIL_8328]  
Lead   
Funding Agency:  
 National Center for Advancing Translational Scie nces  
Version:  
 12.0 
Date:  05JUN [ADDRESS_552620] ID:                              [STUDY_ID_REMOVED] 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 2 Statement of Compliance  
 
This trial will be conducted in compliance with the International Council for Harmonisation 
(ICH) E6 (R2) guideline for Good Clinical Practice (GCP), and the applicable regulatory 
requirements from the [LOCATION_002] (US) Code of Federal Regulations (CFR), including 45 CFR 
46 (Human Subjects Protection); 21 CFR 312 (Investigational New Drug); 21 CFR 50 (Informed Consent), and 21 CFR 56 (Institutional Review Board). 
All individuals who are responsible for the conduct, management, or oversight of this study have 
completed Human Subjects Protection and ICH GCP Training.  
 
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552621] read the protocol, including all appendices, and the package insert (s)/product label (s), and 
I agree that the protocol contains all necessary details for my staff and me to conduct this study 
as described. I will personally oversee the conduct of this study as outlined herein and will make 
a reasonable effort to complete the study within the time designated. I agree to make all 
reasonable efforts to adhere to the attached protocol.  
I will provide all study personnel under my supervision with copi[INVESTIGATOR_436306]’s representative. I will discuss this material with study personnel to ensure that they are fully informed about the efficacy and safety 
parameters and the conduct of the study in general. I am aware that, before beginning this study, 
the IRB , or equivalent oversite entity must approve this protocol in the clinical facility where it 
will be conducted.  
I agree to obtain informed consent from participants, as required by [CONTACT_436349] I CH guidelines. I further agree to report to the sponsor 
or its representative any adverse events in accordance with the t erms of this protocol and the U S 
CFR, Title 21, part 312.64, ICH GCP 4.11. I further agree to ensure the study is conducted in 
accordance with the provisions as stated and will comply with the prevailing local laws and 
customs.  
 
 
   
Site Principal Investigator [CONTACT_5627] (Print)   
   
   
Site Principal Investigator [INVESTIGATOR_88473] -6 Protocol [v12.0] 
 
 4 Table of Contents  
1. Protocol Summary  ........................................................................................................13  
1.1. Synopsis  ..........................................................................................................................13  
1.2. Schema  ............................................................................................................................20  
2. Introduction  ...................................................................................................................22  
2.1. Study Rationale  ...............................................................................................................22  
2.2. Background  .....................................................................................................................22  
2.3. Benefit /Risk Assessment  ................................................................................................[ADDRESS_552622]-acute disease (Appendix G)  ....................................................................................25  
Study Design .................................................................................................................................27  
3.3. Overall Design  ................................................................................................................27  
3.4. End of Study Definition  ..................................................................................................28  
4. Study Population  ...........................................................................................................29  
4.1. Inclusion Criteria  ............................................................................................................29  
4.2. Exclusion Criteria  ...........................................................................................................29  
4.3. Recruitment and Engagement  .........................................................................................29  
4.3.1.  Participant Recruitment  ..................................................................................................29  
4.3.2.  Participant Engagement  ..................................................................................................29  
4.3.3.  Participant Randomization Process.................................................................................30  
4.4. Screen Failures  ................................................................................................................30  
4.5. Enrollment  ......................................................................................................................31  
5. Study Drug(s)  ................................................................................................................32  
5.1. Repurposed Medication Treatments  ...............................................................................32  
5.2. Placebo  ............................................................................................................................32  
5.3. Study Drug Accountability  .............................................................................................32  
5.4. Concomitant Therapy  .....................................................................................................32  
5.5. Intervention After the End of the Study ..........................................................................32  
6. Participant Withdrawal/Termination and Study Termination  ................................33  
6.1. Participant Withdrawal/Termination  ..............................................................................[ADDRESS_552623] to Follow -up............................................................................................................33  
7. Study Assessments and Procedures.............................................................................35  
7.1. Schedule of Events ..........................................................................................................36  
7.1.1.  Screening .........................................................................................................................37  
7.1.2.  Intervention Period..........................................................................................................37  
7.1.3.  Follow -up Period  ............................................................................................................38  
7.1.4.  Final Visit ........................................................................................................................39  
7.2. Clinical Assessments  ......................................................................................................39  
7.3. Quality of Life Questionnaires  .......................................................................................41  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552624] (ADE) and Unanticipated Adverse 
Device Effect (UADE)  ....................................................................................................[ADDRESS_552625] ................................................................................................45  
8.2. Unanticipated Problem (UP) and Terminations ..............................................................46  
8.2.1.  Definition of Unanticipated Problem  ..............................................................................46  
8.2.2.  Reporting of an Unanticipated Problem  .........................................................................46  
9. Statistical Considerations  .............................................................................................47  
9.1. Statistical Hypotheses  .....................................................................................................47  
9.1.1.  Primary Hypothesis  .........................................................................................................47  
9.2. Sample Size Determination  ............................................................................................47  
9.3. Randomization  ................................................................................................................48  
9.4. Blinding ..........................................................................................................................48  
9.5. Populatio ns for Analyses  ................................................................................................48  
9.6. Statistical Analyses  .........................................................................................................49  
9.6.1.  General Considerations  ...................................................................................................49  
9.6.2.  Statistical Modeling  ........................................................................................................49  
9.6.3.  Assessing Effectiveness (Acute Disease Primary Objective)  .........................................49  
9.6.4.  Acute Disease Interim Analyses (IA), Early Stoppi[INVESTIGATOR_007], and Type -
I Error Control .................................................................................................................50  
9.6.5.  Sensitivity and Supplementary Analyses  ........................................................................52  
9.6.6.  Differential Treatment Effects and Subgroup Analyses (Acute Disease)  ...........................................................................................................................52
 
9.6.7.  Secondary Clinical Endpoi nt (Acute Disease)  ................................................................52  
9.6.8.  Exploratory Analysis (Acute Disease)  ............................................................................53  
9.6.9.  Adherence and Retention Analysis  .................................................................................53  
9.7. Interim Reporting  ............................................................................................................53  
9.8. Independent Data Monitoring Committee (IDMC)  ........................................................[ADDRESS_552626] (IRB)  ...................................................................................[ADDRESS_552627] Keepi[INVESTIGATOR_007]  ...........................................................................58  
11.1.  Data Collection and Management Responsibilities  ........................................................58  
11.2.  Study Records Retention  ................................................................................................58  
11.3.  Protocol Deviations .........................................................................................................58  
11.4.  Publication and Data Sharing Policy  ..............................................................................58  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 6 12. Study Leadership ..........................................................................................................60  
13. Summary of Changes ....................................................................................................61  
14. References  ......................................................................................................................69  
15. Appendix A (Enrollment Closed 04FEB2022) – Ivermectin 
[ADDRESS_552628]  ...............................................................................................80  
16. Appendix B (Enrollment Closed 27MAY2022) – Fluvoxamine Maleate  ...................................................................................................[ADDRESS_552629]  ...............................................................................................87  
17. Appendix C (Enrollment Closed 08FEB2022) – Fluticasone Furoate  ...........................................................................................................................88
 
17.1.  Risk Assessment  .............................................................................................................88  
17.2.  Additional Appendix- Level Exclusion Criteria  ..............................................................89  
17.2.1.  Precautions  ......................................................................................................................89  
17.3.  Fluticasone Furoate Information  .....................................................................................89  
17.3.1.  Formulation, Appearance, Packaging, and Labeling  ......................................................90  
17.3.2.  Drug Dispensing, Storage, and Stability  .........................................................................90  
17.3.3.  Dosing and Administration  .............................................................................................90  
17.3.4.  Rationale for Selection of Dose  ......................................................................................90  
17.4.  Placebo Information  ........................................................................................................91  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552630]  ...............................................................................................92  
17.6.  Safety Reporting for Fluticasone Furoate  .......................................................................92  
18. Appendix D (Enrollment Closed 22JUL2022) – Ivermectin 
[ADDRESS_552631]  ...............................................................................................94  
19. Appendix E (Enrollment Closed 20JAN2023) – Fluvoxamine Maleate [ADDRESS_552632]  ...............................................................................................97  
20. Appendix F (Enrollment Closed 23JUN2023) – Montelukast  ..................................98  
20.1.  Risk Assessment  .............................................................................................................98  
20.2.  Additional Appendix- Level Exclusion Criteria  ..............................................................99  
20.2.1.  Precautions  ......................................................................................................................99  
20.3.  Study Drug Information ..................................................................................................99  
20.3.1.  Formulation, Appearanc e, Packaging, and Labeling  ......................................................99  
20.3.2.  Drug Dispensing, Storage, and Stability  .........................................................................99  
20.3.3.  Dosing and Administration  .............................................................................................99  
20.3.4.  Ration ale for Selection of Dose  ......................................................................................99  
20.4.  Placebo Information  ......................................................................................................102  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552633]  .............................................................................................102  
21. Appendix G – Metformin Hydrochloride Immediate-Release  ...............................[ADDRESS_552634] -acute Disease  .........................................................108  
21.7.1.  Primary Hypothesis  .......................................................................................................108  
21.7.2.  Sample Size Considerations  ..........................................................................................108  
21.7.3.  Interim Analysis  ............................................................................................................109  
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552635]  
KO Knockout  
LPS Lipopolysaccharide  
MAOI  Monoamine Oxidase Inhibitors  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552636]-Acute Sequelae  of SARS -CoV -2 Infection  
PCORI  Patient -Centered Outcomes Research Institute  
PCR  Polymerase Chain Reaction  
PHI Personal Health Information  
PHQ  Patient Health Questionnaire  
PI [INVESTIGATOR_436307] S uccess  
PROMIS  Patient -reported Outcomes Measurement Information System  
QOL Quality of Life  
RNA  Ribonucleic Acid  
RRT  Renal Replacement Therapy  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS -CoV -1/2 Severe Acute Respi[INVESTIGATOR_696] S yndrome Coronavirus 1/[ADDRESS_552637]  
UP Unanticipated Problems  
US [LOCATION_002]  
WT Wildtype  
XR Extended -Release  
  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 11 Table of Figures  
Figure 1: ACTIV -6 Study Schema ............................................................................................... 20 
Figure 2. ACTIV -6 Interim Analysis Schema – Acute Disease  ................................................... 21 
Figure 3: Operational Structure Diagram  ..................................................................................... 60 
Figure 4: Survival curve of WT and S1R KO mice  ...................................................................... 85 
Figure 5:  Summary of JAMA Randomizat ion Clinical Trial of Fluvoxamine for Early COVID -
19................................................................................................................................................... 86 
Figure 6:  Summary of study results for the prospective, nonrandomized observational cohort 
study with fluvoxamine in participants diagnosed with COVID -19. ........................................... 86 
Figure 7. Probability of efficacy for the primary outcome in the ITT and mITT populations of 
TOGETHER  ................................................................................................................................. 96 
Figure 8. Mean (SD) plasma metformin concentrations by [CONTACT_436350] a single 
daily dose of metformin.  ............................................................................................................. 105 
Figure 9. Metformin systemic (plasma) exposure ...................................................................... 106 
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552638] of Tables  
Table 1: Schedule of Events  ......................................................................................................... 36 
Table 2: ACTIV -6 Sample Size Estimates and Power  ................................................................. 48 
Table 3: Ivermectin Adverse Event Table for Doses ≥  300 µ g/kg ............................................... 76 
Table 4: Ivermectin 400 Dosing Schedule  .................................................................................... 78 
Table 5. Fluvoxamine Adverse events occurring in 10 -week studies of adult OCD or depression
....................................................................................................................................................... 81 
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants receiving 
300 mg/day for 15 days. ................................................................................................................ 82 
Table 7. Fluticasone Adverse reactions that occurred in ≥3% of adults and adolescents with 
asthma in a [ADDRESS_552639] sodium adverse reactions occurring at a higher incidence than placebo, in ≥1% of adults and adolescents ≥ [ADDRESS_552640]  .................................................................... 101 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 13 1. Protocol Summary  
1.1. Synopsis  
 
Title  ACTIV -6: COVID- 19 Outpatient Randomized Trial to Evaluate 
Efficacy of Repurposed Medications  
Clinical study phase  III 
Rationale  Coronavirus Disease 2019 (COVID -19) is caused by a novel 
coronavirus, severe acute respi[INVESTIGATOR_6507] 2 
(SARS -CoV -2), that first emerged in December  [ADDRESS_552641] been  made for treatment 
of COVID -19 and vaccination for prevention of SARS -CoV -2 
infection. However, the pandemic continues to evolve with new variants and surges of infections in different regions of the world, 
requiri ng an ongoing evidence- generating  clinical trial  platform, in 
particular for the treatment of COVID -19 in the outpatient setting. 
This platform protocol can serve as an evidence generation system for prioritized drugs , repurposed from other Food and Drug 
Administration ( FDA ) indications with an established safety record  
in humans  and preliminary data of efficacy. The ultimate goal is to 
evaluate if repurposed medications can make p articipants feel better 
faster and reduce death and hospi[INVESTIGATOR_059].  
Acute Disease: 
Primary Objective • To evaluate the effectiveness  of repurposed medications  [(study 
drug(s)] in nonhospi[INVESTIGATOR_436308] -19 
Acute Disease: Secondary 
Objectives  • To evaluate the clinical outcomes  in participants in a study drug  
arm versus those in the placebo arm  
• To describe symptom resolution in participants in a study drug 
arm versus those in the placebo arm  
• To describe the quality of life (QOL) in participants in a study drug arm versus those in the placebo arm  
• To compare illness severity trajectories in participants in a study drug arm versus those in the placebo arm  
Acute Disease: Exploratory 
Objective  • To describe long -term COVID -19-related symptoms in 
participants in a study drug  arm versus those in the placebo 
arm  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552642]-acute Disease 
(Appendix G) : 
Primary Objective • To compare the risk  of Post -Acute Sequelae of SARS -CoV -2 
Infection or death (PASCD) at day [ADDRESS_552643]-acute Disease 
(Appendix G) : 
Secondary Objective  • To compare the risk of  PASCD at day [ADDRESS_552644]-acute Disease 
(Appendix G): Exploratory 
Objective  • To compare symptom  burden in participants taking 
metformin versus placebo  
Intervention  All interventions will occur in addition to standard of care. Each 
study drug appendix describes a different study drug and 
matching placebo. The following arms will be included in each 
study  appendix : 
• Study Drug Arm: repurposed medications (see Appendices) 
• Placebo Arm: placebo control  
While each appendix describes  the placebo that matches the 
study drug, for comparative analysis the control group will 
comprise  eligible, concurrent ly enrolled participants from all 
study arms who were assigned to placebo .  
Study Design  This study is a platform  protocol designed to be flexible so that 
it is suitable for a wide range of settings within healthcare systems and in community settings where it can be integrated into routine COVID -19 testing programs and s ubsequent 
treatment plans. Th is platform  protocol will enroll participants in 
an outpatient setting with a confirmed  positive polymerase chain 
reaction ( PCR ) or antigen test for SARS -CoV -2. Each appendix 
will describe a repurposed medication ( study drug ) to meet the 
protocol objectives. 
When only one  study drug/appendix is under study, allocation 
between study drug and placebo will be 1:1. If multiple study 
drugs/appendices  are under study, participants will  also be 
randomized among the study drugs  for wh ich eligibility is 
confirmed. Since the route of administration of each study drug may differ, the placebos may also differ. To achieve blinding 
and an equitable randomization probability, a  two-step 
randomization process will be used . 
In the first step, t he participant will be randomized m :1 active 
study drug  to placebo, where m is the number of active study 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 15 drugs  for which the participant is eligible  (note, if the same 
study drug is tested at multiple doses, each dose will count as 
one study drug). Then, participants  will be  randomized among 
the m study drugs  for which they are eligible. Participants will 
carry their ‘ study drug ’ versus ‘placebo’ randomization with 
them into the s tudy drug appendix. In this way, a participant  
allocated to placebo who is randomized to s tudy drug A will be 
given the placebo that matches s tudy drug A. This achieves 
equal probability of exposure among the placebo and active 
study drugs for which the participant is eligible, and equitable 
distribut ion among all study arms for which a participant is 
eligible.  Sites will be informed to which s tudy drug  appendix the 
participant is  randomized, but not whether they are allocated to 
the study drug  arm or placebo arm within that appendix .  
For analysis, concurrent placebo participants who were eligible for the study  drug  appendix will be pooled. This will result in 
approximately a 1:[ADDRESS_552645] of care, the active study drug  arm may serve 
as a concurrent placebo for other study drugs.  
Each study drug appendix will go through Screening Interim Analyses to assess efficacy /futility  prior to evaluation of the 
primary objective. Thi s Screening Interim Analysis provides an 
innovative approach to evaluate the potential for repurposed 
drugs to reduce symptom burden and prevent disease 
progression in the outpatient setting at various points throughout 
enrollment.  
Participants will receiv e complete supply of repurposed 
medication (study drug) or placebo with length of treatment and amount of study drug/placebo depending on the  study drug 
appendix and arm  to which they are randomized. 
This study is designed so that it can be done completely  
remote ly. However, screening and enrollment may occur in-  
person at sites and unplanned s tudy visit s may occur in -person 
or remotely , as deemed appropriate by [CONTACT_436351] . Participants will be on- study for up to 180 days, 
during which they will complete various questionnaires.  
Population  Up to 15,000 adults   
Study Duration 24 months  
Study Location  Up to 280 sites  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 16 Inclusion Criteria 1. Completed Informed Consent 
2. Age ≥  30 years old  
3. Confirmed SARS-CoV- 2 infection  (or reinfection) by [CONTACT_436352] 10 
days of s creening  
4. Two or more c urrent symptoms of acute infection for ≤  7 days . 
Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, c hills, headache, sore 
throat, nasal symptoms, new loss of sense of taste or smell . 
Exclusion Criteria 1. Current or recent (within 10 days of screening) hospi[INVESTIGATOR_53763]-19 infection 
2. Current or planned participation in another interventional trial to treat COVID -19, at the discretion of the study principal 
investigator (PI)  
3. Current or recent use  (within the last 14 days ) of study drug or 
study drug/device combination*  
4. Known allergy/sensitivity or any hypersensitivity to 
components of the study drug or placebo* 
5. Known contraindication (s) to study drug including prohibited 
concomitant medications (see Appendices)* 
6.  Previous or current enrollment in the ACTIV- 6 trial  
*If only one study drug appendix is open at the time of enrollment. 
If multiple study drug appendices are open, a participant may opt-
out of any study drug appendix or be excluded from any study drug appendix based on contraindications listed in the study drug appendix, current use of study drug, or known 
allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study drug appendi ces. 
Sample Size Considerations This study will enroll up to 15,000 adults, depending on the number of study drug appendice s that are added and adjustments 
to sample size depending on the data.   
Acute disease 
An estimated sample size of approximately 1200 participants per study drug appendix is expected  to be sufficient  to conclude 
whether there is meaningful evidence of benefit  on the  acute 
disease primary objective.  
A screening  interim analyses  (sIA) will occur  at n=300 and 
n=600  to inform termination of the arm, continuation of 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 17 enrollment, or transition to  assessment of the primary objective.  
Formal interim analyses (IAs) of the primary objective are 
planned at n=300, n=600 and n=900. Review of emerging data 
will be done according to the schedule of DSMB meetings; no formal interim analyses are expected after n=900 .  
As described in the statistical analysis plan  (SAP) , the type I 
error for the primary objective is controlled at < 0.05. 
Post-acute Disease ( Appendix G) 
A sample size of [ADDRESS_552646] passed Day 180.  
As described in the SAP, type I error is controlled at < 0.05. 
General Statistical 
Consideration for Acute Disease Primary Analysis  The primary objective of effectiveness will be determined based on the endpoints of hospi[INVESTIGATOR_059] /death  or time to recovery  over [ADDRESS_552647] for this platform (symptoms, 
hospi[INVESTIGATOR_059] , and mortality)  are collected  using a web -assisted 
symptom d iary according to the schedule in Table 1. Symptoms 
will be graded on an ordinal scale as none, mild, moderate, or severe.  
The odds of hospi[INVESTIGATOR_436309] . Time to recovery,  measured as 
the time to achieving three consecutive days of self -reported 
symptom freedom, will be used to draw conclusions about symptom burden.  
The primary analysis will be implemented separately for each study drug, where the matching placebo arm will  consist of concurrently 
randomized participants that meet the inclusion and exclusion criteria for that study drug  appendix. A modified intention to treat 
(mITT) approach will be used for primary analyses ; all participant s 
who receive study drug will be i ncluded as assigned. It is possible 
that the delivery of medications (placebo or study drug) does not occur (failure of delivery, participant death, or participant 
withdrawal) ; this will result in exclusion of the participant for the 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552648] -randomization  
adherence to study protocols.  
Independent Data 
Monitoring 
Committee (IDMC )  Frequent IDMC  reviews will be conduc ted to ensure the safety of 
study participants and evaluate the accumulating endpoint data by 
[CONTACT_1570]. Regular IDMC  meetings will monitor the 
following parameters at a minimum:  
• Recruitment progress  
• Enrollment overall and by [CONTACT_12125]  
• Adherence, ret ention, and status of data collection  
• Serious adverse events  
• Assessment for futility  
• Probability for benefit across endpoints  
Interim Analysis  Interim analyses  (IA) will be performed per s tudy drug appendix , 
after approximately every 300 participants  (~150 in study drug arm 
and ~ 150 in placebo arm) have completed the Day  [ADDRESS_552649] regardless 
of final study drug a rm allocation . The following decision 
thresholds will be checked during  IA(s): 
i) Screening IA (n=300):  
a. The study drug is found to have benefit (efficacy). Study 
drug appendix will proceed to acute disease prim ary 
objective IA at n=300. Note: this is also a check for harm as 
all assessments are two -tailed.  
b. The study drug is not found to have benefit, enrollment 
continues in the study drug appendix and sIA is repeated at 
n=600. 
ii) Screening IA (n=600):  
a. It woul d be futile to attempt to show a benefit of the study 
drug based on the predicted probability of success  (PPOS) 
and other factors . The s tudy drug appendix will be 
terminated.   
b. Futility is not determined.  Study drug appendix will proceed 
to acute disease primary objective IA at n=600.  
iii) Acute Disease Primary Objective IA (n= 300): if  the criteria for 
proceeding to the  acute disease primary objective are met  when 
n=300 , an acute disease  primary objective  IA will be conducted 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 19 for the  acute disease  primary objecti ve when n=300. T he 
following decisions will be assessed:  
a. The study drug is found to have benefit (efficacy), the study 
drug appendix will be terminated as the acute disease 
primary endpoint has been met.  
b. It would be futile to attempt to show a benefit of t he study 
drug based on the PPOS and other factors . The study drug 
appendix will be terminated.  
c. Efficacy/futility is undeterminable, enrollment will continue 
in the study drug appendix and the  acute disease primary 
objective IA will be assessed at n= 600.  
iv) Acute disease Primary Objective IA (n= 600, 900):  if the criteria 
for proceeding to the  acute disease primary objective IA are met 
when n=600 or n=900, a n acute disease primary objective IA 
will be conducted. The following decisions will be assessed:  
a. The study drug is found to have benefit (efficacy), the study 
drug appendix will be terminated as the acute disease 
primary endpoint has been met.  
b. It would be futile to attempt to show a benefit of the study 
drug based on the PPOS and other factors . The study drug 
appendix will be terminated.  
c. Efficacy/futility is undeterminable,  enrollment will continue 
in the study drug appendix and the  acute disease primary 
objective will be assessed after another [ADDRESS_552650] been enrolled, or until n= 900, and then again when 
n=3000. 
v) Interim analyses beyond n=900: subsequent to planned interim 
analyses, the evaluation of continuation of a study arm will 
consider achieving the primary objective, the secondary 
objective of preventing PASC, and any external stakeholder  
evidentiary needs with evaluation according to the schedule of 
DSMB meetings.  
Post-acute D isease (Appendix G)  
i) Secondary Objective IA (n=600 passing Day 90): A  futility 
analysis on the PASCD endpoint will be conducted when [ADDRESS_552651] passed day 90 under the a ssumption of accrual 
to n=3000. 
A posterior probability of meaningful benefit  for a  study drug in 
comparison to the placebo control of greater  than the appendix -
specified threshold  will result in a declaration of  overall  superiority . 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 20 A PPOS when n= 3000  of less than the appendix -specified threshold  
will result in a declaration of futility . 
 
 
 
  
1.2. Schema  
 
 
Figure 1: ACTIV-6 Study Schema  
 

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 21  
Figure 2. ACTIV-6 Interim Analysis Schema  – Acute Disease  

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 22 2. Introduction  
2.1. Study Rationale  
Severe acute respi[INVESTIGATOR_6507] 2 (SARS -CoV -2) is a novel betacoronavirus  that 
first emerged in  December [ADDRESS_552652] to the number of cases and overall mortality. [1, 2] The clinical disease 
related to  SARS -CoV -2 is referred to as Coronavirus Disease 2019 (COVID -19). Since 2020, 
advances have been  made for treatment of COVID -19 and vaccinations  for prevention of SARS -
CoV -2 infection , through emergency use authorization or FDA approval .[3-8] However, the 
pandemic continues to evolve with new variants and surges of infections in different regions of 
the world, requiring an ongoing evidence-generating  platform, in particular for the  treatment of 
COVID -[ADDRESS_552653] -acute sequelae of (PASC) . The ultimate goal is to 
evaluate if repurposed medications can make participants feel better faster and reduce death , 
hospi[INVESTIGATOR_059] , and PASC.  
2.2. Background  
In December  2019, numerous patients in Wuhan, China were diagnosed with pneumonia caused 
by [CONTACT_88529]. By [CONTACT_36466] 7, 2020,  Chinese scientists had isolated SARS -CoV -2. This is 
a novel betacoronavirus clos ely related to severe acute respi[INVESTIGATOR_6507]  1 
(SARS -CoV -1).[2]  In the subsequent months the spread of the virus led to  a global pandemic. 
As of February 7, 2022 there were approximately  395,540,912 confirmed COVID -19 cases 
resulting in  5,741,726 deaths worldwide.[1]  
The virus continue d to spread despi[INVESTIGATOR_436310] , vaccination 
campaigns/requirements,  and travel restrictions. As the pandemic progressed and social 
distancing, masking, and travel restrictions were lifted, the virus continued to spread.  COVID -[ADDRESS_552654] been  distributed  and administered  globally ; however, new SARS -CoV -2 
strains continue to emerge, with potential for reduced monoclonal antibo dy therapeutic and  
vaccine efficacy. [9] As new strains have emerged that confirm t ransmission , infection, and even 
severe disease after vaccination is possible , highlighting the need to establish treatment regimens 
despi[INVESTIGATOR_436311].  Furthermore, acceptance and uptake of booster shots has been 
lower than uptake  of the initial vaccination series, further justifying the need for safe and 
effective therapi[INVESTIGATOR_014].  Thus, there remains a need to identify safe and efficacious  treatments that can 
be administered in the outpatient setting.  
As of February 2022, mu ltiple clinical trials have been reporte d, providing guidance to clinical 
providers on management of COVID -19, particularly in the hospi[INVESTIGATOR_6885]. Various drugs, 
including monoclonal antibodi es and antivirals, have been authorized or approved by [CONTACT_436353] -19.  Multiple repurposed 
immunomodulatory agents are clinically used for the treatment of severe COVID -[ADDRESS_552655] been reported to improve clinical disease and , 
in some cases , mortality .[10, 11] Few of these are therapi[INVESTIGATOR_436312].    
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 23 2.3. Benefit/Risk Assessment  
The risks for participation in this study include taking study drug (see Appendices)  and loss of 
confidentiality . There may be some benefit to the participant if the therapy is effective against 
COVID -19 and/or PASC. 
2.3.1. Risk Assessment  
Loss of confidentiality risks : There is a potential risk of loss of confidentiality. Every effort will 
be made to protect the participant’s confidential medical information, but this cannot be 
guaranteed. Clinical information will not be released without written permission of the participant, except as necessary for monitoring by [CONTACT_1201], FDA, National Institutes of Health (NIH), Office for Human Research Protections (OHRP ), other local, US, and international 
regulatory authorities/entities as part of their duties.  
Risk lowering measures :
  Study procedures to manage and minimize risks include careful 
selection of the participants and monitoring over time to check on participants ’ health. 
Additional guidance to manage any risks  or any change to the risk to the participant  based on 
emerging data will be provided to the study teams, as needed. In addition, an Independent Data Monitoring Committee (IDMC ) will monitor safety of the participants throughout the study.  
2.3.2. Benefit Assessment  
Participants who randomize to a study drug arm may benefit from study drug administration.  
There is no direct benefit to participants randomized to the placebo arm  apart from participating 
in generating evidence that may ultimately support treatment for SARS-CoV- 2 infection  and it’s 
complications. In addition, they will benefit from involvement with the team following their health status during the study. The knowledge gained  will be a benefit to others in the future.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 24 3. Objectives and Endpoints 
3.1. Acute d isease  
Objectives  Outcome Measurement s Reported Endpoints 
Primary    
To evaluate the 
effectiveness  of repurposed 
medications  [(study drug(s)] 
in nonhospi[INVESTIGATOR_436313] -19 • Hospi[INVESTIGATOR_436314] 28  
• Time to r ecovery  over [ADDRESS_552656] day 
of  three consecutive days of self-reported symptom freedom Odds ratio (OR) for clinical events or hazard ratio (HR) for time to recovery will be used to estimate treatment effect.  
Secondary   
To evaluate the clinical outcomes  in participants in 
a study drug arm versus those in the placebo arm  • COVID Clinical Progression Scale on Day 7, Day 14, and Day 28 (see Section 8.2) 
• Mortality through Day 28 
• Hospi[INVESTIGATOR_059], urgent care visit, e mergency 
room visit through Day 28 The following model-assisted endpoints will be 
reported for the COVID Clinical Progression Scale: 
• The OR describing the 
difference in clinical progress ion at each 
measured time point  
• The HR describing the 
difference in time to 
hospi[INVESTIGATOR_436315]: 
• Time to first urgent care, emergency care, hospi[INVESTIGATOR_436316] a study drug arm versus those in the placebo arm  Symptom resolution, defined as  three co nsecutive days without 
symptoms  Time to symptom resolution  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 25 To describe the quality of 
life (QOL) in  participants in 
a study drug arm versus those in the placebo arm  Modified Patient-Reported 
Outcomes Measurement Information System (PROMIS)-29 at baseline, Day 7, Day 14, Day 28, Day 90 , and Day 120
1 
Follow-up • Odds ratios (ORs ) specific 
to days 7, 14, 28, 90, and 120
1 
• The OR  in QOL scores at 
each time point  
To compare illness severity trajectories in participants in a study drug arm versus those in the placebo  arm Ordinal outcome including symptom severity, hospi[INVESTIGATOR_059] , and death 
measured daily for 14 days • Difference in mean time unwell 
• Mean days of benefit 
Exploratory   
To describe long -term 
COVID -19-related 
symptoms in participants in a study drug arm versus those in the placebo arm  Symptom occurrence, type, and severity at Day 90 , Day 120
1, or 
Day 1801 Follow-up 
 Directly measured mean and median symptom count and QOL score at Day 90 , Day 
120
1, or Day 1801 in study 
drug arm(s) versus placebo 
3.2. Post-acute disease1 (Appendix G)  
Objectives  Outcome Measurements  Reported Endpoints 
Primary    
To compare the risk  of Post-
Acute Sequelae of SARS -
CoV- 2 Infection or death 
(PASCD) at day 180 in participants taking metformin  versus placebo  • Patient reported symptom 
burden  
• Mortality status  through day 
180 The difference i n risk of 
PASCD at day 180 between groups 
Secondary   
To compare the risk of  
PASCD at days 90 and 120 in participants taking  
metformin  versus placebo  • Mortality status through day 
180  
• Patient reported symptom 
burden • The d ifference i n risk of 
PASCD at days 90 and 120 between groups 
• The risk ratio of PASCD at days 90, 120, and 180 between groups 
                                                 
1 Day 180 is applicable only for participants who were consented to the study after protocol v7.0 was implemented; 
Day 120 is applicable only for  participants consented under protocol v6.0; Day 90 was the final follow -up day for 
Ivermectin 400,  Ivermectin 6 00, Fluvoxamine Maleate, and Fluticasone Furoate . 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 26 Exploratory   
To compare symptom 
burden in participants taking metformin versus placebo  • PASC Symptom 
Questionnaire • The difference  between 
metformin and placebo 
responses for [ADDRESS_552657]-exertional malaise  
o Weakness (arms/legs)  
o Pain (limbs)  
o Faintness  
o Gastrointestinal upset  
o Color changes to skin 
o Dry mouth 
o Concentration 
o Confusion 
o Forgetfulness 
o Focus 
o Mental Clarity  
o Overall health  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 27 Study Design 
Refer to Section 1.2 for the Study Schema. 
This study includes an innovative screening approach using sIA s to make decisions about  
droppi[INVESTIGATOR_436317], or to accelerate study of potentially effecti ve agents . Each 
study drug appendix will go through s IAs to assess efficacy /futility  prior to evaluation of the 
primary objective. This  sIA provides an innovative approach to evaluate the potential for 
repurposed drugs to reduce symptom burden and prevent disease progression at various points 
throughout enrollment  in a broad population. 
3.3. Overall  Design  
This study is a platform  protocol designed to be flexible so that it is suitable for a wide range of 
settings within healthcare systems and in community settings where it can be integrated into 
routine COVID -19 testing programs and subsequent treatment plans. The platform  protocol will 
enroll participants  with mild to moderate COVID -19 in an outpatient setting with a confirmed 
positive polymerase chain reaction ( PCR ) or antigen test  for SARS -CoV -2 infection . Each 
appendix will describe a repurposed medication ( study drug  arm) that  is sized to meet the master 
protocol objectives. 
Participants will be randomized to one of the study drug  appendices  that are actively enrolling at 
the time of randomization. Study drug  appendices  may be added or removed according to 
adaptive design and/o r emerging evidence. When there  are multiple study drug a ppendices  
available, randomization will occur based on appropriateness of each drug for the participant  as 
determined by [CONTACT_88531]. Each participan t 
will be required to randomize to at least one study drug versus placebo.  The probability of 
placebo to treatment will remain the same regardless of eligibility  decisions.   
Eligible participants will be randomized (1:1), in a blinded fashion, to either th e study drug  
arm or placebo arm  in addition to standard of care , when one active drug is on the platform or 
when a participant is only eligible for one of the active drugs on the platform . As additional 
study drug  appendices  are added, the randomization wi ll be altered to leverage placebo data 
across arms . If a study drug is offered at two doses, each dose  will be treated  as separate study 
arm. If a participant is eligible for [ADDRESS_552658] a 1:[ADDRESS_552659] a 2:1 chance of receiving 
an active study drug, for 3 arms it is 3:1, for 4 arms it is 4:1, and so on. This is because each 
participant assigned to a placebo group is shared among all appendices, and the goal is that within appendices the allocation probability to study drug  versus placebo is 1:1.  Participants 
will receive a complete supply of repurposed medication (study drug) or placebo with the quantity  depending on the study drug/placebo to which  they are randomize d. 
All study visits are designed to be remote. However, screening and enrollment may occur in -
person at sites and unplanned study visit s may occur in -person or remotely , as deemed 
appropriate by [CONTACT_88532] . Parti cipants will be asked to complete 
questionnaires and report  safety events  during the study, according to Table 1. Participants will 
be prompted by [CONTACT_436354], as necessary .  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552660] completed the study if he/she has completed the applicable 
Long -term Follow -up assessments , refer to Table 1.  
The end of the study is defined as the date of the last follow -up of the last participant in the 
study . Data from interim analyses or recommendations  by [CONTACT_88534].   
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 29 4. Study Population  
All Eligibility Criteria will be obtained per participant.   
4.1. Inclusion Criteria  
1. Completed Informed Consent  
2. Age ≥ 30 years old  
3.   Confirmed SARS -CoV -2 infection  (or reinfection) by [CONTACT_436355] 10 days of s creening  
4. Two or more c urrent symptoms of acute infection for ≤ 7 days . Symptoms include the 
following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches , chills, 
headache, sore throat, nasal symptoms, new loss of sense of taste or smell  
4.2. Excl usion Criteria  
1. Current or recent (within 10 days of screening) hospi[INVESTIGATOR_436318] -19 infection  
2. Current or planned participation in another interventional trial to treat COVID -19, at the 
discretion of the study principal investigator (PI)  
3. Current or recent  use (within the last 14 days ) of study drug or study drug/device 
combination *  
4. Known allergy/sensitivity or any hypersensitivity to components of the study drug or  
placebo * 
5. Known contraindication (s) to study drug  including prohibited concomitant medications 
(see Appendices)* 
6.  Previous or current enrollment in the ACTIV -6 trial  
*If only one study drug appendix is open at the time of enrollment. If multiple study drug 
appendices are open, a participant may opt -out of any study drug appendix or be 
excluded from any study drug appendix based on contraindications listed in the study drug appendix , current use  of study drug, or known allergy/sensitivity/hypersensitivity 
and still remain eligible for the remaining study drug appendices.  
4.3. Recruitment and Engagement  
4.3.1. Participant Recruitment  
Participants who are eligible based on positive SARS -CoV -[ADDRESS_552661] will be 
identified by [CONTACT_88536] -identify to a central study hotline(s)  and be referred to 
the closest site. Site investigators, or their designee, may  contact [CONTACT_88537].  
4.3.2. Participant Engagement  
Participants will be engaged in the study  through multiple channels. This includes , but is not 
limited to , ongoing participation in other registries partnering with ACTIV or healthcare systems.  
Additionally, p articipant engagement will include:  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 30 • compensation for participants who complete the applicable Final Visit  (Day 90, 120, or 
180);  
• creating a study -wide ACTIV -6 Advisory Group;  
• developi[INVESTIGATOR_88488] -centered approaches that recognize the needs and preferences of 
COVID -19 survivors locally  and nationally ; and 
• multifaceted approaches that combine engagement tool s, leverage the online system , use 
of social media, and representative COVID-Participants . 
4.3.3. Participant Randomization Process  
This trial is a double -blind, placebo- controlled trial. Participants and investigators will be 
blinded. A participant who is eligible for m study drug arms /appendices  will be randomized m :1 
study drug  to placebo ( Figure 1). The participant will then be randomized with 1/ m probability 
to each of the study drug appendices . A participant entering a study drug appendix carries their 
study drug  or placebo designatio n with them and will get either the study drug  or matching 
placebo. Participants who receive placebo will be pooled across study drug arms for those study 
drug arms /appendices  that the participant is eligible. This reduces overall sample size by 
[CONTACT_436356] a 1:1 allocation to study 
drug or placebo within an appendix . Randomization sequences will not be pre- generated. Given 
the adaptive nature of the trial and the unknown number of study drug  appendices , arm  
assignment will be implemented at the time of confirming eligibility for randomization  using a 
random number generator. The participant eligibility criteria will be checked for each study  drug  
appendix, and the randomization probabilities will b e set. The two step procedure will then 
occur, and the assignment to both s tudy drug  appendix and study drug  versus placebo will be 
made. The participant and study teams will know w hich s tudy drug  appendix the participant is 
allocated to , but will be blinded to study drug versus placebo because they will be matching.  
The participant, treating clinicians, and study personnel will remain blinded to study drug versus 
placebo  assignment until after the database is locked and blinded analysis is completed.  Only the 
biostatistical team who is preparing closed IDMC  interim reports will be unblinded. Specifically, 
study drug/placebo will be dispensed with packaging and labelling that would blind treatment assignment. Unblinding will occur only if required for participant  safety or treatment at the 
request of the treating clinician . Refer to the Manual of Procedures (MOP) for further details.  
4.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study , who 
fulfill  inclusion and exclusion criteria,  but are not subsequently  randomized. Screen failures also 
include participants who consent, then on review by [CONTACT_779], are found to be ineligible for the study. A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participant s to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities.   
Individuals who are considered screen failures  may not be re -screened.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 31 4.5. Enrollment  
Participants who are randomized and receive study drug/placebo will be considered enrolled. 
Participants who are randomized, but do not receive study drug/placebo for any reason (e.g., study drug lost in the mail , death prior to receipt of study drug, participant withdrawal prior to 
receipt of study drug ), will not be considered enrolled on the study and will be identified as 
randomized not enrolled . 
Receipt of study drug will be defined as evidence that the study drug was delivered to the 
address of record.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 32 5. Study Drug (s) 
5.1. Repurposed Medication Treatments  
See Appendices  
5.2. Placebo  
See Appendices  
5.3. Study Drug Accountability  
Use of study drug will be tracke d via the online system , call center , or sites . Participants will 
dispose of any unused study drug as they would normally when stoppi[INVESTIGATOR_007] a medication. 
5.4. Concomitant Therapy  
Select concomitant medications of interest  that the participant is receiving at the time of 
enrollment or receives during the course of the study  will be recorded along with dosing 
information. Select concomitant medications of interest include the following  and will be 
verified at each remote visit by [CONTACT_51015] : 
• Any t herapeutics that is th ought to have potential  or purported COVID activity  including 
hydroxychloroquine  
• Antibiotics  
• Antifungals  
• Antiparasitic  
• Antivirals including HIV protease inhibitors and ribavirin  
• Immunosuppressants including steroids  
• Angiotensin -converting -enzyme (ACE)/angiotensin II receptor blockers 
(ARB) /angiotensin receptor neprilysin inhibitor ( ARNI ) 
• Statin 
• Anticoagulants and antiplatelets  
• COVID -19 vaccine (before, during, or after study intervention) 
Refer to the MOP for more details on concomitant therapy. Refer to the appendices for 
contraindicated  medications for each of the study drugs.  
5.5. Intervention A fter the End of the Study  
No additional study drug will be provided to the participant following completion of the study.   
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 33 6. Participant Withdrawal /Termination  and Study Termination  
6.1. Participant Withdrawal/Termination  
Participants will be followed until participant closeout, withdrawal of consent, or death.  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons. This is expected to be uncommon.  
Those who request withdraw al from the study will be asked to continue on study follow -up with 
limited participation t hrough the Final Visit ( Section 8.1.4). Limited participation may include a 
call(s) to assess safety  at study visits following withdrawal . 
If the part icipant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected befor e such a withdrawal of consent.  
6.2. Premature Termination or Suspension of the Study  
The study  may  be temporarily suspend ed or prematurely terminated if there is sufficient 
reasonable cause. Written notification will be provided documenting reason for study suspension or termination to the investigators, funding agency, and regulatory authorities , as appropriate . 
Circumstances  that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or eval uable  
• Determination of futility after a sufficient time has passed for accrual of the primary and 
secondary outcomes  
• Recommendation by [CONTACT_31849]  
6.3. Lost to Follow -up 
Participants will be asked for proxy contacts to assess vital status and/or other clinical events , 
including safety,  if a participant fails to provide the information. Provision of proxy information 
is not required for study participation. A participant  will be considered lost to follow -up if he or 
she repeatedly fails to  complete study assessments/procedures  as outlined below  and neither the 
participant nor the participant’s  proxy can  be contact[CONTACT_9298].  
The following actions must be taken if a participant  fails to provide baseline information, if he or 
she fail to complete daily symptom reporting by [CONTACT_88539]/placebo  (Day 2), if he or she miss one  daily sympto m reporting  during Days 3 to 14, 
if he or she miss either the Day 14  or Day 28 Remote Visit s, and/or he or she fail to complete the 
applicable Final Visit  assessments : 
• The site or call center  must attempt to contact [CONTACT_401634] c ounsel the participant  
on the importance of completing study assessments/procedures . 
• The site or call center will contact [CONTACT_2299]’s proxy to assess vital status and/ or 
other clinical or safety events.  
• The site or call center will attempt to collect all missing survey  responses . 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 34 • Before a  participant  is deemed lost to f ollow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635]  (where possible, three  telephone calls 
and, if necessary , a certified letter to the participant ’s last known mailing address or 
local equivalent methods). These contact [CONTACT_21457] ’s research  record.  
• Online obituary search .    
• Should the participant  continue to be unreachable, they  will be considered lost to 
follow -up.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552662] be verified prior to randomization (refer to the MOP for details ). Sites will be 
responsible for notifying the coordinating center for participant w ithdrawals, lost to follow -up, 
permanent cessation of study drug, study drug dose modifications  (if allowed, per Appendix), or 
change in vital status. Data will be collected directly from the participant and supported by 
[CONTACT_30219], as needed.  
  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 36 7.1. Schedule of Events  
 
Table 1: Schedule of Events 
                                                 
2 Day 180 is applicable only for participants who were consented after  protocol v7.0 was implemented; Day 120 is applicable 
only for  participants consented on protocol v6.0 ; Day [ADDRESS_552663] pregnancy listed as a contraindication for females of childbearing 
potential. Participants will self -report pregnancy using the Pregnancy Reasonably Excluded Guide.  
5 Review only during study drug/placebo administration if contraindicated medications provided for the study drug arm, per 
Appendix.  
6 Day 14 only.  
7 Daily symptom reporting; continued daily beyond day 14 through day 28 until symptoms resolve for > 3 consecutive days. All 
participants will complete symptom reporting on Days 21 and 28, regardless of symptom resolution.  
8 Day 7 and 14 only . 
9 Day 3, 7, and 14 only.  
10 At Day 7 and 14 for participants enrolled in Appendix E – Fluvoxamine Maleate 100.  
11 At Day 14 for participants enrolled in Appendix G – Metformin Hydrochloride Immediate -Release.  
12 Participant’s medical record will be reviewed to confirm Serious Adverse Events (SAEs), Unanticipated Adverse Device 
Events (UADEs) [as applicable], and Events of Special Interest (ESIs).   
 
 
 
 
 
 
 
 Screening  Intervention 
Period  Follow -up Period  
 Final 
Visit  Unplanned 
Study Visit  
Day 
Within 7 days 
of Day 1  
Day 1  
Days 2 - 14 
Day 15 - 20 
Day 21 ± 2  
Day 22 - 27 
Day 28 + 5  
Day 902 + 5 
Day 1202 + 5 
Day 1802 + 7 
 
ACTIV -6 Trial             
Consent  X           
Demographic Information  X           
Eligibility criteria confirmed  X           
Randomization  X           
Receipt of study drug or placebo   X          
Continued use study drug   Continuous3         
Clinical Assessments        
  
  
    
Abbreviated medical history  X           
Self-reported Pregnancy  X4           
Concomitant Therapy  X X5 X5 
         
Remote Visit    X6    X     
Drug Adherence   X X 
         
COVID -19 Outcomes   X X8 
  X  X X X X  
Symptom Reporting  X7 X X7 
 X7 X7 X7 X7 X X X  
PASC Symptom Questionnaire           X  
QOL Questionnaire  X  X8    X X X X  
At-home pulse oximetry    X9         
Columbia -Suicide Severity Rating 
Scale (C -SSRS)    X10         
Hypoglycemia Reporting    X11         
Safety Assessment12  Continuous via online system and medical record review  X 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 37 7.1.1. Screening  
The following events will occur at Screening : 
• Consent : Participants will be consented either via an e-consent process or paper process. 
The consent process should be done in accordance with local and central IRB  regulations. 
Phone consenting may be facilitated through the e-consent or paper process. 
• Demographic information will be collected including , but not limited to, age, sex, race,  
ethnicity , and occupation  
• Eligibility criteria confirmation  by [CONTACT_88541] 
a paper process 
• Abbreviated medical history  
• Self-reported pregnancy, for women of childbearing potential (only for enrollment in 
Study Drug Appendices that include pregnancy as a contraindication )  
• Concomitant therapy   
• Symptom reporting , daily  during screening period 
• QOL questionnaire 
• Randomization  (see Section 5.3.3) 
7.1.2. Intervention Period  
The following events will occur during the Intervention Period, starting with receipt of study 
drug/ placebo : 
Day 1:  
• Receipt of study drug or placebo 
• Study drug self- administration  (see Appendices for specific study drug/placebo 
administration)  
• Concomitant therapy   
• Drug adherence questionnaire 
• COVID -19 Outcomes 
• Symptom reporting 
• SAE , UADE (as applicable),  and ESI collection  
Days 2 – 14: 
• Study drug self- administration  (see Appendices for specific study drug/placebo 
administration)  
• Concomitant therapy , including contraindicated medications provided for the study drug 
arm, per Appendix, during study drug/placebo administration. 
• Remote visit  (Day 14 only ) 
• Drug adherence questionnaire, daily  
• COVID -19 Outcomes (Day 7 and 14 only) 
• Symptom reporting , daily  
• QOL questionnaire (Day 7  and 14 only) 
• At-home pulse oximetry readings (Day 3, 7, and 14 only)  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 38 • C-SSRS ( Day 7 and 14 for Appendix E – Fluvoxamine Maleate 100 only ) 
• Hypoglycemia reporting ( Day 14 for Appendix G – Metformin Hydrochloride 
Immediate -Release only ) 
• SAE , UADE (as applicable),  and ESI collection  
7.1.3. Follow -up Period  
Day 15  – 20:  
• Symptom reporting, daily from Day [ADDRESS_552664] not  yet reported three 
consecutive days of no symptoms. Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be followed daily. 
• SAE , UADE (as applicable),  and ESI collection  
Day 21 ± 2 days:  
• COVID -19 Outcomes 
• Symptom reporting 
• SAE , UADE (as applicable),  and ESI collection  
Day 22  – 27:  
• Symptom reporting, daily from Day [ADDRESS_552665] not  yet reported three 
consecutive days of no symptoms. Participants who experience three days of improvement before Day 14 but who then experience symptoms again will not be followed daily. 
• SAE , UADE (as applicable),  and ESI collection  
Day 28 + 5 days: 
• Remote visit  
• COVID -19 Outcomes 
• Symptom reporting 
• QOL questionnaire 
• SAE , UADE (as applicable),  and ESI collection  
Day 90 + 5 days:  
• COVID -19 Outcomes 
• Symptom reporting 
• QOL questionnaire 
• SAE, UADE (as applicable), and ESI collection  
The Day 120 + 5 days Follow- up visit is only applicable for participants consented on protocol 
v6.0 or later and will include the following :  
• COVID -19 Outcomes 
• Symptom reporting 
• QOL questionnaire 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 39 • SAE, UADE (as applicable), and ESI collectio n 
7.1.4. Final Visit  
Depending on when the participant was consented, the Final Visit may have occurred at Day 90 
or Day 120. Following implementatio n of protocol v7.0, Day 180 + 7 days will serve as the Final 
Visit. The Final Visit will include the following:   
• COVID -19 Outcomes 
• Symptom reporting 
• Post-acute Sequelae of SARS -CoV- 2 Infection (PASC ) Symptom Questionnaire (Day 
180 participants  only) 
• QOL questionnaire 
• SAE , UADE (as applicable),  and ESI collection  
7.2. Clinical  Assessments  
Abbreviated Medical History : smoking status, estimated body mass index (BMI)/obesity, pre-
existing underlying lung disease (e.g. , chronic obstructive pulmonary disease, asthma, idiopathic 
pulmonary fibrosis), underlying immunosuppression (transplant, malignancy, human immunodeficiency virus ( HIV), autoimmune disease), medical conditions that may increase risk 
of COVID-19 infections or complications (e.g., diabetes, cardiovascular disease, hypertension, chronic kidney disease), venous thromboembolism, chronic liver disease, COVID -[ADDRESS_552666]:  
 Concomitant medications of interest, including study drug 
specific contraindicated medications, will be collected. Refer to Section 6.[ADDRESS_552667] and to the study drug specific appendices for contraindicated medications.  
Self-reported Pregnancy: Participants will be asked to self -report pregnancy, as needed, per 
Study Drug Appendix. The 3- item “Pregnancy Reasonably Excluded Guide” will be used to 
assess pregnancy at screening. The “Pregnancy Reasonably Exc luded Guide” uses traditional and 
World Health Organization criteria to exclude pregnancy via participant self -report.[12] Refer to 
the MOP for details.   
Remote Visit : Designated  study personnel will contact [CONTACT_88542] a phone call or 
other form of direct contact (e.g., text or e- mail survey)  in order to conduct study assessments , 
includ ing, but not limited to, COVID-19 outcomes, drug adherence (at Day 14), and safety 
events . A missed remote visit will be considered a protocol deviation  (non- major) . If a 
participant misses a remote visit, site study staff should take immediate action to contact [CONTACT_2299], per Section 
7.3 follow-up processes. Refer to the MOP for details.  
Drug Adherence:  Adherence to the study drug administration schedule will be collected via the 
online system  and confirmed at the Day 14 remote visit. 
COVID -19  Outcomes : The COVID -19 outcomes for this trial are based on the World Health 
Organization’s Ordinal Scale for Clinical Improvement and  will be collected via the online 
system  and from the medical record .[13] The following outcomes will be assessed  as part of the 
COVID Clinical Progression  Scale:   
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 40 0. No clinical or virological evidence of infection  
1. No limitation of activities  
2. Limitation  of activities  
3. Hospi[INVESTIGATOR_057] , no oxygen therapy 
4. Hospi[INVESTIGATOR_057] , on oxygen by [CONTACT_88543] 
5. Hospi[INVESTIGATOR_057] , on non- invasive ventilation or high -flow oxygen 
6. Hospi[INVESTIGATOR_057] , on intubation and mechanical ventilation  
7. Hospi[INVESTIGATOR_057], on ventilation + addi tional organ support – pressors, RRT, ECMO 
8. Death  
Symptom Reporting: Symptoms and symptom- related responses will be reported by [CONTACT_88544] . Additional symptom reporting may  occur from the sites, as 
available. Each of pre-defined symptoms will be assessed on an ordinal severity scale of none, 
mild, moderate, and severe.  The following symptoms will be collected :  
• Overall symptom burden 
• Fatigue  
• Dyspnea - shortness of breath or difficulty breathing at rest or with activity  
• Fever  
• Cough  
• Nausea  
• Vomiting  
• Diarrhea 
• Body aches  
• Sore throat 
• Headache  
• Chills  
• Nasal symptoms  
• New l oss of sense of taste or smell  
• Other COVID- related symptom   
Post-acute Sequelae of SARS -CoV- 2 Infection (PASC) Symptom Questionnaire : COVID -19 has 
affected m any lives through lingering symptoms, often debilitating long after acute SARS -CoV-
2 infection. The syndrome of PASC is a chronic condition present in up to 80% of infected, 
hospi[INVESTIGATOR_2764] 40% to 70% of non- hospi[INVESTIGATOR_9643].  [14-18] The PASC Symptom 
Questio nnaire includes symptoms that are associated with PASC and ask s for severity 
(mild/moderate/severe) related to any symptoms identified  by [CONTACT_3038] . 
At-ho me pulse oximetry measurements : Participants will provide pulse oximetry readings using 
a study -provided FDA -approved pulse oximeter. Two consecutive pulse oximetry readings must 
be reported at each required time point . Day 3, 7, and Day 14 are study-required time points  for 
pulse oximetry readings. Participants can  report pulse oximetry readings at other times 
throughout the study, at their own discretion.   
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 41 7.3. Quality of Life Questionnaires  
The following QO L questionnaire will be u sed in this study: 
• Modified PROMIS -29: PROMIS measures were developed through a collaborative 
process funded by [CONTACT_18121].[19] The PROMIS-29 consists of seven health domains with 
four 5- level items  associated with each and a pain intensity assessment using a 0 -10 
numeric rank. The seven health domains include physical function, fatigue, pain 
interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance.[20] The PROMIS -[ADDRESS_552668] questions from each of the seven health domains, refer to the MOP for details.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552669] of a clinical trial. An AE can therefore be any change in clinical 
status, routine labs, x- rays, physical examinations, etc., that is considered clinically significant b y 
the study investigator .  
An SAE or serious suspected adverse reaction or serious adverse reaction as determined by [CONTACT_88545]:  
• Death  
• Life-threatening AE (“life- threatening” means that the study participant was, in the 
opi[INVESTIGATOR_26335], at immediate risk of death from the reaction as it occurred and required immediate intervention)  
• Persistent or significant incapacity or substantial d isruption of the ability to conduct 
normal life functions  
• Inpatient hospi[INVESTIGATOR_1081]  
• Congenital abnormality or birth defect  
• Important medical event that may not result in one of the above outcomes, but may 
jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event  
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline does not meet the definition of an SAE. Hospi[INVESTIGATOR_31561] a stay in the 
hospi[INVESTIGATOR_88489] [ADDRESS_552670] (ADE) and Unanticipated Adverse Device Effect (UADE) 
For those repurposed medications that are a part of a combination product, which includes a drug 
and a device, the following additional definitions will apply . 
An ADE is an AE related to th e use of an investigational medical device. This includes any AE 
resulting from insufficiencies or inadequacies in the instructions for use, the deployment, the implantation, the installation, the operation, or any malfunction of the repurposed medical 
device. This also includes any event that is a result of a use error or intentional misuse.  
• Device malfunction – the failure of a device to perform in accordance with the 
instructions for use or clinical investigative plan.  
• User error or intentional misuse – A device is used in a manner that is an act or omission 
of an act that results in a different medical device response than intended by [CONTACT_3460]. 
A UADE is any SAE  caused by, or associated with, a device, if that effect, prob lem, or death 
was not previously identified in nature, severity, or degree of incidence in the investigational 
plan or applications (including a supplemental plan or application), or any other unanticipated 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 43 serious problem associated with a device that rel ates to the rights, safety, or welfare of 
participants.  
Unanticipated Adverse Device Effects  (UADEs)  will include events meeting either A or B as 
stated below:  
A. Events meeting ALL of the following criteria:  
• Not included in the relevant appendices or Product  Label  
• Related to the device per site PI [INVESTIGATOR_1238]/or IND sponsor  
• Serious (meets any of the following criteria):  
o Is life- threatening illness or injury  
o Results in permanent impairment of a body function or a body structure  
o Necessitates medical or surgical intervention to prevent permanent 
impairment of a body function or a body structure  
o Results in hospi[INVESTIGATOR_059]  
o Led to fetal distress, fetal death, or congenital abnormality or birth defect  
o Led to death  
(Permanent means irreversible impairment or damage to a body structure or function, exclu ding 
trivial impairment or damage ). 
B. Any other unanticipated serious problem associated with the device that relates to the 
rights, safety, or welfare of participants. 
8.1.2. Collecti on Period for AE and SAE Information  
Study participants (and their designated emergency proxies) will be instructed to report E SIs per 
appendix and Section 9.1.5, SAEs , and U ADEs  through their access t o the study’s online system . 
Each day for 14 days, the participant will be asked to report on their symptoms and health state, 
including hospi[INVESTIGATOR_139074]/or other change in health condition. The assessments include 
specific questi ons pertaining to ESIs, as well as symptoms  and severity , health care visits, 
medications and a notification to the participant to contact [CONTACT_88547]. If the participant is still report ing symptoms at Day 14, they will co ntinue to be 
assessed until they have experienced three consecutive days without symptoms, or until D ay 28, 
whichever is shorter. At Day 28, Day 90, Day 120, and Day 180, participants will complete 
assessments . Safety reporting will be available to the participant continuously throughout the 
study, but will only be required at the aforementioned collection points.   
The daily and follow -up assessments , as described in the paragraph above, will be monitored  and 
sites will be actively notified of events requiring review, including for reporting that meets 
criteria for ESIs, SAE s, or U ADEs . Refer to the MOP for details. In addition, participants will be 
invited during assessments to request contact [CONTACT_175964], or to report any unusual circumstances that might be relevant, if they so wish. Failure to complete daily assessments is also a trigger for review of a possible SAE. A missed assessment  on the day after receiving  the 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552671] dose of study medication (Day  2) or any day  of missed assessments  up to Day [ADDRESS_552672] access to event 
reporting via the online system  from the signing of the informed consent form (ICF) until the 
Final Visit (Day 90, Day 120, or Day 180 depending on the time of consent ). 
Events of special interest (ESIs) and SAEs  will be extracted by [CONTACT_436357]’s medical record  if the participant seeks medical care or if hospi[INVESTIGATOR_221255] , 
each of which notifies the site to conduct follow up.  
Medical occurrences that begin before the start of study drug/placebo, but after obtaining 
informed consent , will not be considered an AE. 
Non-serious AEs  (or ADEs, as applicable)  may be reported by [CONTACT_2299], but will not be 
further assessed by [CONTACT_88549] E SI.  
Events of Special Interes t (ESIs) , SAEs , and U ADEs (as applicable)  will be collected from the 
start of study drug/device combination  until the Final Visit (Day 90, Day 120, or Day 180 
depending on the time of consent ) or until [ADDRESS_552673] dose /use of device  if participant 
terminates the study  early . 
8.1.3. Assessing Causality of a Serious Adverse Event  
If an SAE occurs, the site investigator  or medical monitor  will assess the relationship to study 
drug by [CONTACT_88550]:  
• Related:  
o Study drug – t here is a temporal relationship between study drug  and event onset 
or the event abates when study drug is discontinued or known to occur with study drug. 
o Device – an event is due to the use of the device and cannot be reasonably 
explained by [CONTACT_88551].  
• Not related: The event has no temporal relationship to study drug  (or study device, as 
applicable)  or the AE  (or ADE, as applicable)  has a much mor e likely alternate etiology 
or is due to an underlying or concurrent illness or effect of another drug  (or device, as 
applicable) . 
8.1.4. Reporting and Monitoring of SAEs  
All of the study drugs used in this platform  protocol  are repurposed medications that are 
approved for marketing in the US  for another medical condition. However, their investigational 
use for treatment  of COVID -[ADDRESS_552674] to IND regulation s in 21 CFR 312. The IND sponsor or designee will review SAEs 
weekly, and will perform aggregate reviews of SAEs every two weeks. The IND sponsor or her designee will be responsible for determining if the safety reporting criteria are met per 21 CFR 
312.32(c)(1)(i)(C) and 21 CFR 312.32(c)(1)(iv) and will notify the Data Coordinating Center 
(DCC ) to prepare an aggregate report for submission to the FDA. An aggregate safety report will 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552675] from the Agency following the submission of any 
aggregate reports.  
Any UADE(s) that the IND sponsor determines is/are reportable will be submitted to the FDA, 
manufacturer, all reviewing IRBs, and all participating investigators within [ADDRESS_552676].  
All hospi[INVESTIGATOR_88491] (see Section 10.9), any event that is 
determined to be COVID -19-related will not be reportable as an expedited SAE , with the 
exception of events that are related to study drug and unexpected, which will be repo rtable 
regardless of relatedness to COVID -19. All events that are not  COVID -19-related per the 
adjudication process will be reviewed by [CONTACT_436358] a reportable SAE.  
Individual S AEs and UADEs must be entered  into the data system within 24 hours of site 
awareness. The DCRI Safety Surveillance  team  will notify pharmaceutical partners of SAEs 
within 1 business day of their receipt that occur involving the specific appendix of the supplied 
study drug/placebo, as required. Serious Adverse Events that are related and confirmed unlisted 
by [CONTACT_88553]; as  7-day reports 
for unexpected fatal or life -threatening adverse reactions and 15 -day reports for serious and 
unexpected adverse reactions. If the IND sponsor, IDMC , or FDA note a clinically important 
increase in the rate of a S[LOCATION_003]R, the IND sponsor or her de signee will notify investigators no 
later than 15 calendar days after determining that the information qualifies for reporting. The investigator will follow all reportable events until resolution, stabilization or the event is 
otherwise explained. The DCRI  Safety Surveillance Team will follow all SAEs until resolution, 
stabilization, until otherwise explained.  
Pregnancies that occur while on -study will be collected and will not be followed to outcome if 
outcome occurs beyond the participant’s Final Study Vi sit, however, any associated ESI or SAE 
should be reported if information can be collected and entered into the EDC. The DCRI Safety 
Surveillance team will notify pharmaceutical partners of a pregnancy within 1 business day of 
receipt that occur involving the specific appendix of the supplied study drug/placebo,  as 
required.  
8.1.5. Events of Special Interest  
The following are also considered ESIs  to the study  and will be collected by [CONTACT_88554][INVESTIGATOR_88492] :  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 46 • Hypoxia, defined as two consecutive pulse oximetry readings ≤ 93% 
Each study drug may have a unique list of possible related ESIs. Refer to the relevant 
appendices. 
8.2. Unanticipated Problem ( UP) and Terminations  
8.2.1. Definition of Unanticipated Problem   
The OHRP considers UPs involving risks to participants or others to include, in general, any 
incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature,  severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the participant 
population being studie d. 
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]).  
• Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. 
8.2.2. Reporting of an Unanticipated Problem  
The site investigator will report UPs for their p articipants to the DCC. The site may also be 
required to inform their reviewing IRB about a UP occurring at the local institution. The UP 
report to the DCC will include the following:  
• A detailed description of the event, incident, experience, or outcome  
• An explanation of the basis for determining that the event, incident, experience, or 
outcome represents an UP  
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP  
• The DCC  will d ocument and review all UPs.  Details of the UP -reporting process will be 
located in the MOP.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552677] reduced disease progression to hospi[INVESTIGATOR_436319]/or more rapid resolution of 
symptoms  as compared to those who receive placebo.  
For the post -acute disease hypothesis, see Appendix G, Section 21.7.1. 
9.2. Sample Size Determination  
This study is designed to be analyzed using a Bayesian approach, accepting the possibility of 
adding and droppi[INVESTIGATOR_88493]. There is also the  potential for extending 
accrual in a study  drug  appendix if there is the potential to demonstrate benefit. Detailed 
simulations will be used to demonstrate the operating characteristics common to each study drug appendix. Decision thresholds will be set t o balance overall power with control of the 
Type I error rate  in the context of the appendix- specific goal .  
To aid planning for this trial, symptom count  and clinical event data were estimated from 
participants in a clinical trial with similar inclusion criteria. Data were not collected daily in that 
study, but evaluations were completed on Day 10 after randomization, which is considered a 
clinically meaningful point in time. Based on the observed distribution, it is estimated that  
studies of about n= 600 (300 study drug and 300 placebo) will be sufficiently sized to determine 
whether there is evidence of meaningful benefit  per the acute disease primary objective with 
>85% power (Table 2). Moreover, when a  study drug  demonstrates overall effectiveness, the 
planned adaptations to increase targeted accrual for the purpose of demonstrating benefit on 
clinical events is a reasonable extension within the contex t of this platform. The final  decision 
thresholds and operating characteristics selected for  each appendix , if deviating from the 
common approach described in the SAP,  will be customized  in an appendix- specific SAP.
 An 
estimated sample size of approximately 1200 participants per study drug appendix is expected to be sufficient to conclude whether there is meaningful evidence of benefit  on the primary 
objective. It is expected that t his study will enroll up to 15,000 a dults, depending on the number 
of study drug  appendice s that are added and adjustments to sample size depending on the 
data.
[21]  
For sample size details of post -acute disease, s ee Appendix G,  Section 21.7.1.  
 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 48 Table 2: ACTIV-6 Sample Size Estimates and Power  
OR Corresponding 
difference in mean 
symptom burden  Power  Corresponding Risk Difference in clinical 
events  Power  
80%  85%  90%  80%  85%  90%  
0.4 2.10 75 86 101 0.025  343 392 459 
0.5 1.98 132 150 176 0.021  455 520 608 
0.6 1.86 242 277 324 0.017  675 772 903 
0.7 1.74 496 567 664 0.012  1004  1148  1343  
0.8 1.61 1267  1449  1696  0.009  1652  1889  2211  
The sample sizes given are the sample size for the study drug  arm only. Placebos will be borrowed across study drug 
appendices . The total size of the placebo arm  will be equal to the size of the study drug arm. The total number of 
placebos in the trial wil l depend on eligibility of participants among the study drug appendices  and the number of study 
drugs . The calculations are based on symptom burden, hospi[INVESTIGATOR_059], and death at Day 10.  
9.3. Randomization 
See Section 5.3.3 for additional details.   
9.4. Blinding  
The investigators, treating clinicians, and study participants  will all remain blinded to study drug 
versus placebo  assignment until after the database is locked and blinded analysis is completed. 
Only the Investigational Drug Service (IDS ) and staff who are handling randomization codes and 
unblinded  member s of the biostatistical team who are preparing closed IDMC  inter im reports 
will be unblinded. The statistical staff responsible for preparing IDMC  reports will not directly 
interact with the clinical team that delivers care to the study participants. Specifically, study 
medication will be dispensed with packaging and labelling that would blind treatment assignment. Unblinding will occur only if required for participant  safety or treatment at the 
request of the treating clinician.  
The web -based randomization system  will include blind -breaking instructions. Participant s afety 
must always be the first consideration in making an unblinding determination. If the investigator decides that unblinding is warranted, the investigator should complete an unblinding request, which will immediately notify the Medical Monitor  (see MOP for details).  
9.5. Populations for Analyses 
Modified Intention to Treat ( mITT) Population:  
● All participants  who receive study drug/placebo . 
● Participants who do not receive study drug, for any reason, will be excluded ; while this 
modifies the intention to treat principle,  the failure of delivery of medications from site to 
participant is not under the control o f either investigator nor participants and is expected 
to occur infrequently and randomly. Similarly,  early death o f a participant or withdrawa l 
prior to the study drug being received is possible, but unlikely and expected to occur randomly between study drug appendices . All other participants will be included, and 
they will be analyzed according to which arm they were assigned. Thus, the m ITT 
analysis set includes all participants  who were randomized and received the study drug. 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 49 Safety Population:  
● The safety population will include those persons in the mITT population who report 
taking at least one dose of study drug or matching placebo . In the unlikely case a 
participant receives the incorrect study drug, participant s will be grouped according to the 
treatments that they received.  
9.6. Statistical Analyses 
The main trial SAP will be finalized prior to the primary analysis.  It will include a d escription of 
the statistical analyses and detailed simulations used to inform the sample size estimates. 
Appendix- specific decisions, such as choice of covariates  for the model, and context specific 
decisions such as deviations in decision making threshol ds or in targeted accrual, will be made 
blinded to data and prior to analyses. Such decisions will be documented in the trial master file.  
This section is a brief summary of the planned approach to statistical analyses of the most 
important endpoints incl uding primary and secondary endpoints.   
For statistical analysis details  of post- acute disease, See Appendix G, Section 21.7.  
9.6.1. General C onsiderations  
Baseline demographic and clinical variables will be summarized for each randomized arm of the study. Descriptive summaries of the distribution of continuous variables  will be presented in 
terms of percentiles (e.g., median, 25th and 75th percentiles) along with means and standard deviations. Categorical variables will be summarized in terms of frequencies and percentages. Histograms and boxplots may be used to visualize the data.  
If an efficacy signal is observed at n=300  or n=600 following sIA, the trial will enter  assessment 
of the acute disease primary objective. At th at time, the pre-determined primary clinical endpoint 
for the appendix will be evaluated as either clinical events  (hospi[INVESTIGATOR_30059]) or time to 
recovery. The unselected endpoint will be reported as part of the secondary objective. Both clinical endpoints will be analyzed using a covariate- adjusted statistical model.  
9.6.2. Statistical M odeling  
Estimation and inferences about the effect of each study drug versus matching placebo will be made using Bayesian regression methods . For acute disease outcomes, at  least [ADDRESS_552678] of concurrently 
randomized participants that meet the inclusion and exclusion criteria for that study drug.  The 
statistical models are described in detail in the SAP . Briefly, a longitudinal ordinal regression 
model will be used for the s IA, a logistic regression model will be used for clinical events, and 
proportional hazards models will be used for time to event analyses.  All models will be adjusted 
for covariates, including baseline symptom severity  and time from symptom onset. Covariates 
will be formally specified prior to an analysis , considering emerging data and changing context.   
9.6.3. Assessing Effectiveness (Acute Disease Primary Objective)  
The overall effect of each study drug versus matching placebo will be quantified using one of the following two primary endpoints, unless otherwise specified in the appendix: composite clinical 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 50 events (hospi[INVESTIGATOR_30059]) or time to recovery . The pri mary endpoint  will be defined and 
documented per study drug appendix prior to the initial IA . 
The primary analysis will be implemented separately for each study  drug  appendix where the 
matching placebo arm will consist of concurrently randomized participan ts that meet the 
inclusion and exclusion criteria for that study drug . Decision thresholds, priors, and meaningful 
effect sizes may change during the course of the pandemic, as vaccination rates, case rates, and 
new therapi[INVESTIGATOR_436320]. T hresholds, effect sizes and priors, that vary during the trial  
from those described in the main SAP  will be documented  in the trial master file or other 
designated document . Prior to any interim or final analysis, all decision thresholds, priors and 
effect  sizes will be confirmed and evaluated using extensive simulations to demonstrate the 
overall Type I error rate remains below 0.05.  
An mITT approach will be used  for primary analyses. All available data will be used to compare 
each study drug  versus placebo control, regardless of post -randomization adherence to study 
protocols.  
9.6.4. Acute Disease Interim Analyses (IA) , Early Stoppi[INVESTIGATOR_007], and Type -I Error Control  
Individual study drugs may require different sample sizes, and the sample sizes may be adjusted 
based on the results of IA . Therefore, fixed enrol lment triggers will be used for IA . An IA  will 
occur after enrol lment and completio n of 14- day follow -up of approximately every 300 
participants in a study arm  (150 in study drug arm and 150 in placebo arm) . Beyond n=900, IA 
will occur according the DSMB meeting schedule. S tudy drug appendi ces may be stopped early 
for efficacy or futility  (see Figure 2). Thre sholds are de scribed  in the SAP to guide stoppi[INVESTIGATOR_436321] .  
The following schedule and decision thresholds will be followed  for IA s: 
i) Screening IA (n=300):  
a. The study drug is found to have benefit (efficacy). Study drug appendix will 
proceed to primary objective IA at n=300. Note: this is also a check for harm as 
all assessments are two -tailed.  
b. The study drug is not found to have benefit, enrollment continue s in the study 
drug appendix and sIA is repeated at n=600. 
ii) Screening IA (n=600):  
a. It would be futile to attempt to show a benefit of the study drug based on the 
predicted probability of success  (PPOS) and other factors . The study drug 
appendix will be termi nated.  
b. Futility is not determined . Study drug appendix will proceed to primary objective 
IA at n=600. 
iii) Primary Objective IA (n=300): if the criteria for proceeding  to the primary objective 
are met when n=300, a primary objective IA will be conducted. The following 
decisions will be assessed:  
a. The study drug is found to have benefit (efficacy), the study drug appendix will 
be terminated as the primary endpoint has been met.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 51 b. It would be futile to attempt to show a benefit of the study drug within the PPOS 
and other factors . The study drug appendix will be terminated.  
c. Efficacy/futility is undeterminable,  enrollment will continue in the study drug 
appendix and the primary objective IA will be assessed at n= 600.  
iv) Primary Objective IA (n=600 , 900): if the criteri a for proceeding  to the primary 
objective IA are met when n=600 or n=900, a primary objective IA will be conducted. The following decisions will be assessed : 
a. The study drug is found to have benefit (efficacy), the study drug appendix will be terminated as the primary endpoint has been met.  
b. It would be futile to attempt to show a benefit of the study drug based on the PPOS and other factors . The study drug appendix will be terminated.  
c. Efficacy/futility is undeterminable,  enrollment will continue in the stud y drug 
appendix and the primary objective will be assessed after another [ADDRESS_552679] been enrolled, or until n= 900, and then again at n=3000.  
v) Secondary Objective IA (n=600 passing Day 90): A  futility analysis on the PASC 
endpoint will be conduct ed when [ADDRESS_552680] passed day 90 under the 
assumption of accrual to n=3000.  
Interim analyses beyond n=900: subsequent to planned interim analyses, the evaluation of 
continuation of a study arm will consider achieving the primary objective, the s econdary 
objective of preventing PASC, and any external stakeholder evidentiary needs with evaluation 
according to the schedule of DSMB meetings. The analysis for the sIA will use a covariate 
adjusted statistical model. The outcome is an ordinal variable, w hich is the overall symptom 
burden measured on a none  / mild  / moderate /  severe scale with hospi[INVESTIGATOR_436322] 5
th and 6th level of the ordinal scale. The outcome is measured daily for 14 days. The 
outcome is compared between participants receiving study drug and participants receiving 
placebo each of the 14 days using a longitudinal statistical model that considers  the repeated 
measurements on each participant. The statistical model can be used to estimate the days of 
benefit – the number of days for which being on an active study drug results in a better outcome 
than being on a comparator. Days benefit, restated in terms of concordance and discordance probabilities, is the difference between (a) the probability that the intervention is better and (b) the probability that the non -intervention is better, summed over all the days of follow -up. This is 
the main quantity, or estim and, that will be used to make early go/no -go decisions for each 
appendix.  
The primary objective IA will follow processes described in Section 10.6.3 for assessment of efficacy. The primary en dpoint  used for the primary objective IA  will be selected  per appendix 
prior to the  initial  IA.  
A posterior probability of meaningful benefit for a study drug in comparison to the placebo control of greater than the specified threshold will result in a declaration of overall superiority. A 
PPOS when n= 3000 is less than the specified threshold will result in a declaration of futility.  
Futility is a low probability of achieving any conclusions within a reasonable t ime frame or 
within the context of the trial . Prior to each IA , the target date for study completion will be 
specified, and accrual will be projected by [CONTACT_88528]. A statistical model may be used to 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552681] 5% , as described in the SAP . 
9.6.5. Sensitivity and Supplementary Analyses 
The sensitivity analyses described in the SAP  are designed to test robustness of the results to 
assumptions in the statistical mode ls. In addition to checking assumptions about the modeling 
approach, association of adherence with outcomes  will also be ascertained . In the main statistical 
mode l, the number of doses of study drug consumed or weight adjusted dose will be added  as a 
covariate to investigate a possible dose response curve. 
9.6.6. Differential T reatment Effects and Subgroup A nalyses (Acute D isease)  
Differential treatment effect, also referred to as heterogeneity of treatment effect, refers to 
differences in treatment efficacy as a function of pre- existing participant  characteristics such as 
baseline variables. This is often assessed by [CONTACT_436359]. However, these subgroups do 
not inherit the baseline covariate adjustment of the full participant  outcome model, and are 
problematic because of improper subgroupi[INVESTIGATOR_143395] a continuous variable is used. For example, 
dichotomizing age at [ADDRESS_552682] and their uncertainties across age = 10, 11, …, 100. Differential 
treatment effects by [CONTACT_4321], body mass index, and age will be examined . Prior to the final analysis, 
additional important subgroupi[INVESTIGATOR_436323]. Knowledge 
about concomitant therapi[INVESTIGATOR_014], risk factors, and vaccinations are expected to continue to evolve 
and inform the final decision on their inclusion  in these analyses .  
Studies under this master protocol will be sized only for assessing overall study drug effects. 
Thus, there may be inadequate power to (1) examine interactions and to (2) estimate covariate-
specific treatment effects ( e.g., odds ratio at age 70 or for females ). 
9.6.7. Secondary Clinical Endpoint  (Acute D isease)  
The COVID Clinical Progression  Scale score on Day 1 4 will be compared between participants  
in each study drug  arm and the placebo arm  using a covariate adjusted proportional odds model . 
A similar approach will be used for QOL and PASC score outcomes. Covariates will be 
prespecified and will include at a minimum: age, baseline severity, and duration of illness . The 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552683] three consecutive days 
without symptoms, a proportional hazards model will be used. Since death is a competing risk, 
cause- specif ic hazards  will be estimated . Observations will be censored at 28 days.  
9.6.8. Explorat ory Analysis  (Acute D isease)  
Exploratory analyses involve the same outcome variables, measured at [ADDRESS_552684] of treatment on long term outcomes, the SAP will describe how participant  state during the intervention period will be used to inform 
longer te rm outcomes.  
9.6.9. Adherence and Retention Analysis  
Withdrawals from study drug  and consent withdrawals will be tracked via the online system .  
Participants will be asked about  their use of study drug . Those reporting discontinuation or 
switching will be asked about the reasons for discontinuation/switching.   
Measures of study retention to inform follow -up time will be based on several measures, 
including web -based check -ins for symptoms and COVID -19 outcome reporting . 
9.7. Interim Reporting   
In addition to routine evaluation of decision thresholds pursuant to the statistical design of this 
study, regular IDMC  reviews will be conducted to ensure the safety of study participants.  
Regular IDMC  meetings will monitor the following parameters at a minimum:  
• Recruitment progress  
• Enrollment overall and by [CONTACT_12125]  
• Adherence, retention, and status of data collection  
• Events of special interest  (ESIs)  
• Unanticipated problems  
• Serious adverse events  (SAEs)  
Interim examination of clinical endpoints will be based on the accrual of primary endpoint data.  
It is expected that reviews of the data will occur approximately after each 300 participants  are 
enrolled in each study drug appendix (150 in study drug arm a nd 150 in placebo arm).  
For ethical reasons, interim examinations of key safety and process data will be performed at regular intervals during the course of the trial. The DCC  will create reports to track parti cipan t 
enrollment, rates of adherence with the assigned treatment strategy, and frequency of protocol violations. Prior to each meeting, the DCC  will conduct any requested statistical analyses and 
prepare a summary report along with the following information: pa rticipant enrollment reports, 
rates of adherence with the assigned treatment, and description of SAEs.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552685] rule for early termination.  It is expected that both internal and external factors will 
influence the decisions of the IDMC . The SAP  will describe the planned interim analyses and 
futility monitoring in detail . 
9.8. Independent Data Monitoring Committee  (IDMC ) 
The IDMC  will monitor participant safety and study performance. A n IDMC  charter that outlines 
the operating guidelines for the committee and the procedures for the interim eval uations of 
study data will be developed and agreed upon by [CONTACT_31849] . Reports will be prepared by [CONTACT_88558], or as requested by [CONTACT_88559], and 
will include interim analyses of primary and secondary endp oints, additional safety events, and 
other information as requested by [CONTACT_942]. After each scheduled closed meeting, the 
IDMC  will send a recommendation to the IND sponsor to continue, modify , or terminate the 
study. After approval, the recommendatio ns will be forwarded by [CONTACT_436360] 
(CCC) to investigators for submission to their local, regional and national IRB /Ethic 
Committees, as applicable. Please refer to the IDMC  Charter for further details . 
9.9. Adjudication Committee  
The medical records  will be requested  for all participants reporting a hospi[INVESTIGATOR_139074]/or de ath 
at any point during the study. For each participant -reported hospi[INVESTIGATOR_88505], t he 
DCRI Clinical Ev ent Ascertainment (CEA)  group will review the m edical records and confirm 
the occurrence and root cause of the event as part of an adjudication process . The CEA group 
includes specialists relevant to the hospi[INVESTIGATOR_436324], additional details 
about review procedures will be provided in an adjudication charter.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552686] (IRB)  
The protocol, ICF(s) , recruitment materials, and all participant materi als will be submitted to the 
IRB(s)  of record for review and approval . This approval must be obtained before any participant 
is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_1201](s) 
before being implemented in the study. All changes to the consent form will also be IR B-
approved and a determination will be made regarding whether previously consented participants need to be re -consented.  
10.2. Informed Consent Process  
All consenting will occur either via an electronic consent process  or a paper process . Consent 
forms describing in detail the study drug/placebo, study procedures, and risks will be  given to the 
participant and documentation of informed consent is required prior to starting study procedures. Informed consent is a process that is initiated prior to the individual’s  agreement  to participate in 
the study and continues throughout the individual’s study participation. A description  of risks 
and possible benefits of participation will be provided to the participants.  A description of the 
current available therapi[INVESTIGATOR_436325] . Consent forms will be IRB- approved and the participant will be asked to read and 
review the document. The participant will be provided a phone number and email in the event 
they have questions about study participation. This will allow them to communicate with the investigator s (or their delegate) , for further explana tion of the research study and to answer any 
questions that may arise, as necessary . Participants will have the opportunity to carefully review 
the consent form and ask questions prior to signing.  
The participants sho uld have the opportunity to discuss the study and think about it prior to 
agreeing to participate. The participant will sign the informed consent document prior to any 
procedures being done specifically for the study. The participants may withdraw consent at any 
time throughout the course of the study. A copy of the informed consent document will be provided to the participants for their records. The rights and welfare of the participants will be 
protected by [CONTACT_40749].  
The study team will distinguish between the desire to discontinue study drug and the desire to 
withdraw consent for study follow -up. In the event that a participant wit hdraws consent, the 
investigator or his /her designee will clarify with the participant and document whether the 
withdrawal is temporary or permanent, and if a full or partial withdrawal.  
10.3. Participant and Data Confidentiality 
Participant confidentiality is s trictly held in trust by [CONTACT_3486], their staff, 
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples in addition to the clinical and private information relating to participants . Therefore, the 
study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552687] party without prior written approval of the sponsor. The study participant’s contact 
[CONTACT_436361].  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at t he DCC. The study data entry and study 
management systems used by [CONTACT_436362]. At the end of the study, all study -related data storage systems  will be archived  
according to local processes . 
10.4. Site Management and Quality Assurance  
The study team will work in tandem to ensure that the data collected in this study are as complete and correct as possible. A  four- step, multi -functional approach to quality control  will be 
implemented : 
• Training: Prior to the start of enrollment, the clinician investigators and key study 
personnel  at each site will be trained with the clinical protocol and data collection 
procedures, including how to use the Electronic Data Capture (EDC) system. Follow -up 
training and training for new study personnel or new versions of the protocol will be 
conducted as needed.  
• Monitoring: The CCC, along with the DCC, will ensure that data collection is handled 
properly, will provide in- service training, and will address qu estions from site 
investigators and coordinators. Electronic r eview  of data quality and completeness  will 
occur on a  regular and ongoing basis. Any issues will be address ed. At a minimum, 
source document verification will occur, as needed, for confirmation of COVID -19 
diagnosis and hospi[INVESTIGATOR_059](s).  
• Managing data: After the data have been transferred for statistical summarization, data 
description, and data analysis, further crosschecking of the data will be performed with discrepant observations being fl agged and appropriately resolved through a data query 
system.  
• Reviewing data: Data regarding events of interest will be reviewed to ensure appropriate 
documents are collected for IDMC  review. The DCC will monitor standardized 
classification of symptoms  and contact [CONTACT_88562].  
10.5. Site Monitoring  
This study will employ a centralized risk -based approach to monitoring with routine and periodic 
review of participant -submitted data to validate the informed consent process, select eligibility 
criteria, hospi[INVESTIGATOR_059], identify and follow -up on missing data, inconsistent data, data outliers, 
etc. and ensure completion of administrative and regulatory processes.  The study team will 
facilitate regular communication through training sessions, teleconferences, videoconferencing, 
email, etc. Using quality -by-design principles , steps  will be taken at the study design stage to 
foresee and limit problems that might occur during the study conduct. Follow -up fr om the online 
system  and call center is expected to keep participants engaged. Minimal levels of intervention 
and a focus on observing rather than influencing the study participants greatly increases the 
likelihood that Good Clinical Practices will be foll owed. Central statistical monitoring is 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 57 particularly useful for identifying unusual patterns in data. An  integrated approach to quality 
surveillance will be deployed , which will be detailed in the appropriate study management plans.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552688] ( HIPAA) compliant.  
Site personnel or participants will enter study data into a secure online database. D ata will be 
maintain ed in a secure online database until the time of study publication. At the time of 
publication, the DCC will generate a de- identified version of the database  for archiving (see 
Section 12.4).  
11.2. Study Records Retention  
Study documents should be  retained for a minimum of six  years after the study has ended. 
However, if required by [CONTACT_427], these documents should be retained for a longer 
period. No records will be destroyed without the written consent of the sponsor, if applicable. It 
is the responsibility of the sponsor to inform the investigator when these documents no longer 
need to be retained.  
11.3. Protocol Deviations  
A prot ocol deviation is  defined as  non-compliance with the  clinical study  protocol, GCP, or 
MOP requirements. The  non- compliance may be on the part of the partici pant, site inv estigator, 
or the si te staff.  
A major  protocol deviation is a significant divergence from the protocol that may have 
significant effect on the participant ’s safety, rights, or welfare and/or on the integrity of the study 
data. Major protocol deviations  must be sent to the study IRB and l ocal I RB per t heir guidelines, 
recorded in s ource  documents, and re ported t o the coordinating center. Major protocol deviations 
will be tracked . For this study, any missed or delayed survey completion will not be considered a 
major protocol deviation. Refer to the MOP for details.  
11.4. Publication and Data Sharing Policy  
This st udy will comply with the NIH Public  Access Policy, which  ensures that the public has 
access to the results of NIH -funded res earch. Methods of data sharing will include 1) archiving 
de-identified data in a data repository and 2) sharing of limited datasets under a Data Use 
Agreement (DUA) and IRB approval. Data will be made avai lable to qualified investigators by 
[CONTACT_88563] a fully de -identified dataset in  a platform to be determined at the end of the trial . Both 
repositories allow users to search, view study information, and then submit an application to receive data. Prior to ar chiving study dat a, the DCC will produce a final dataset that will be 
stripped of all personal health information (PHI) in compliance with the HIPAA privacy rule. 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552689] peer -reviewed 
journals. The International C ommittee of Medical Journal  Editors (ICM JE) member journa ls have  
adopt ed a cli nical studies  registration policy as a condition for publicat ion. The ICMJE defines a 
clinical study as  any research projec t that prospe ctively assigns human participants  to 
intervention or concu rrent c omparison or control groups t o study the cause-and-effect 
relationsh ip between a medical intervention and a  health outcome. The ICMJE  policy, and the 
Section [ADDRESS_552690] of 2007, requires t hat all 
clinical studies be regi stered in a public registry such as ClinicalTrials .gov, which is spons ored 
by [CONTACT_88564]. For interventional cli nical trials per formed und er NIH IC 
grants and cooperative agreements, it is the gra ntee’s responsibility to register the study in an 
acceptable registry, so the res earch results  may be considered for publicati on in  ICMJE  member 
journals.   
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 60 12. Study Leadership  
The Steering Committee is a multi -stakeholder committee that oversees the study and includes 
representatives from clinical sites, the trial coordinating center, the NIH, PCORI, Operation 
Warp Speed, the FDA , National Center for Advancing Translational Sciences (NCATS), ACTIV 
representatives with no conflict of interest, and academic and industry advocates .  
The CCC and DCC are ea ch overseen  by [CONTACT_976](s). The CCC is responsible for study coordination, 
site management, communication, and financial administrat ion. The DCC is responsible for 
treatment allocations, receipt and processing of data, quality control programs, and statistical 
analysis and reporting.   
An independent IDMC  will oversee the safety and welfare o f trial participants as well as provide 
recommendations for continuation, discontinuation or revision of the trial.  
 
 
Figure 3: Operational Structure Diagram  

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 61 13. Summary of Changes  
Protocol Version (version #, date)  Summary of Changes  
Version 1.0, 01APR2021  N/A, Version 1.0 
Version 2.0, 25MAY2021  • Added current use of study drug or study 
drug/device combination as an exclusion 
criterion  (Sections 1.1 and 5.2);  
• Added a  phone call follow -up the day 
after first study drug dose , clarified that 
follow -up will occur if two consecutive 
days of reporting are missed during Days 
3-14, and added that sites/call center will 
collect missing survey information during 
follow -up calls (Section 7.3);  
• Added at-home pulse oximetry readings 
and description of at -home pulse oximetry 
reading collection ( Table 1 and Section 
8.2); 
• Added symptom severity scale (Section 8.2); 
• Added Adverse Device Effect and 
Unanticipated Adverse Device Effects definitions, collection/reporting period details, and causality assessment details (Sections 9.1.1, 9.1.2, 9.1.3, 9.1.4);  
• Clarified that hypoxia ESI will only be collected from hospi[INVESTIGATOR_88492] (Section 9.1.5);  
• Clarified that any missing or delayed survey completion will not be considered a major protocol deviation (Section 12.3);  
• Updated Ivermectin and matched placebo 
information and packaging (Sections 16.3, 16.3.1, 16.3.3, 16.4.1);  
• Added Appendix B – Fluvoxamine 
maleate (Section 17);  
• Added Appendix C – Fluticasone Furoate 
(Section 18);  
• Changed symptom freedom to symptom resolution for consistency throughout;  
• Other administrative changes throughout.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 62 Version 3.0, 06JUL 2021  • Clarified that the sample size increase will 
include 1:1 active study drug to placebo 
(Section 1.1);  
• Added footnote 6 to COVID -19 
Outcomes during Intervention Period to clarify that these will be assessed on Day 7 and 14 (Table 1);  
• Added that events that are COVID -19 
related AND study drug related and unexpected will be considered reportable (Section 9.1.4);  
• Updates made to fluvoxamine appendix: excluded linezolid , use of fluoxetine 
within 45 days of consent, and bipolar disorder per FDA feedback (Section 17.2); added precautions of additional drugs including t ramadol, buspi[INVESTIGATOR_5331], 
fentanyl, lithium, a mphetamines, St. 
John’s Wart, carbamazepi[INVESTIGATOR_050], quinidine, and tacrine per FDA feedback (Section 17.2.1);  
• Updates made to fluticasone furoate 
appendix: brand name [CONTACT_436378] (Section 18); changed liver failure exclusion criteria to “m oderate to 
severe hepatic impairment, defined as Child- Pugh B or C”  (Section 18.2); 
removed hepatic impairment precautions as it was added to exclusion criteria (Section 18.2.1);  
• Other minor administrative changes throughout . 
Version 4.0, 20DEC2021 • Removed protocol number as no p rotocol 
number will be assigned;  
• Changed primary objective from symptom reduction to effectiveness based on clinical outcome endpoints of hospi[INVESTIGATOR_059]/death or time to recovery 
(Sections 1.1 and 3);  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 63 • Removed unnecess ary “ e.g., 
hospi[INVESTIGATOR_9017]” from first 
secondary objective ( Sections 1.1 and 3);   
• Added rationale  for sIA (Sections 1.1 and 
4);  
• Inclusion criterion #3:  added reinfection 
(Sections 1.1 and 5.1);  
• Exclusion criteria updates: Removed “prior diagnosis of COVID -19 infection 
(>10 days from sc reening)” as it was 
causing confusion for sites and is already covered by [CONTACT_436363] #3; specified that current or recent hospi[INVESTIGATOR_53763] -19 infection is 
exclusionary, not all hospi[INVESTIGATOR_602]; added a time window for current or recent use of study drug or combination for within the last 14 days; added “current or planned participation in another interventional trial to treat COVID -19, at 
the discretion of the study PI ” (Sections 
1.1 and 5.2);  
• Sample size considerations updated to include sIA (Sections 1.1 and 10.2);  
• Statistical considerations for Primary Analysis updated to align with change in primary objective and IAs (Section s 1.1, 
10.6.1, and 10.6.3);  
• Interim Analysis updated to specify that IA will occur ~ every 300 participants instead of every 200, included sIA, and primary objective IA (Sections 1.1, 10.6.4, and 10.7);  
• Added Figure 2 to portray IA process (Section 1.2);  
• Updated study background and rationale based on new data (Sectio ns 2.1 and 2.2);  
• Updated secondary outcome measures and reported endpoints (Section 3);   
• Added additional informati on regarding 
arm eligibility depending on the number 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 64 of arms open to provide clarity for sites 
(Section 4.1); 
• Added that screen failures also include 
participants who  consent, then on review 
by [CONTACT_779], are found to be ineligible for the study (Section 5.4);  
• Added additional reasons why participant may not receive study drug/placebo and specified that these participants would be identified as randomized not enrolled, instead of consented not enrolled (Section 5.5); 
• Specified that par ticipants will be 
contact[CONTACT_436364] 3 to 14 (Section s 7.3 and 9.1.2);  
• Clarified that all participants will be asked to complete symptom reporting on Days 21 and 28, regardless of symptom resolution (Table 1, Section 8.1.3) ; 
• Added that “overall symptom burden” is collected as part of Symptom Reporting (Secti on 8.2);  
• Updated primary hypothesis to align with updated primary objective (Section 10.1.1);  
• Model priors section removed and Statistical modeling simplified to refer to detailed description in SAP as models will 
be adjusted per appendix (Section 10.6.2);  
• Removed details of sensitivity analysis and referred to SAP (Section 10.6.5);  
• Clarified that additional subgroupi[INVESTIGATOR_436326] (Section 10.6.6);  
• Changed Appendix A – Ivermectin title to 
Ivermectin 400 (Section 16); removed CYP3A4 and P -gp precautions as not 
noted in the IB for the ivermectin stud y 
drug (Section 16.2.1); in Section 16.2
, 
deleted “use of warfarin, CYP3A4, P -gp 
inhibitor drugs, or CYP3A4 substrates” 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 65 appendix -level exclusion criteria and 
added “Current or planned use of the 
following drugs:  
o Antiarrhythmic/antihypertensive drug class: quinidine, amiodarone, diltiazem, spi[INVESTIGATOR_8407], verapamil  
o Antibiotic- macrolides drug class: 
clarithromycin, erythromycin  
o Antifungal drug class: itraconazole, ketoconazole  
o Immunosuppressant drug class: cyclosporine, tacrolimus  
o Anti-HIV drug class: indinavir, 
ritonavir” ; 
• Added Appendix D – Ivermectin 600 
(Section 19);  
• Other administrative changes  throughout. 
Version 5.0, 17MAR2022  • Added illness severity objective (Sections 1.1 and 3);  
• Removed reference to appendix -specific 
SAP, only significant deviations from the main SAP analysis will require appendix -
specific SAPs. Choice of primary objective, covariates, etc. will be documented outside of the SAP (Sections 1.1, 10.2, 10.6, 10.6.3, 10.6.4);  
• Clarified that primary objective occurs at 28 days (Sections 1.1 and 3);  
• Updated COVID -19 status, vaccination, 
and treatment options background (Sections 1.1 and 2.1);  
• Defined “receipt of study drug” (Section 5.5); 
• COVID -19 vaccination added to 
abbreviated medical history (Section 8.2);  
• Updated instructions for unblinding (Section 10.4);  
• Specified that covariates will take into account emerging data and changing 
context (Section 10.6.2 ); 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 66 • Added that t his study operates in addition 
to usual care in additional protocol 
locations (Sections 11.2 and 2.1);  
• Appendix A closed to enrollment on 04FEB2022;  
• Appendix C closed to enrollment on 08FEB2022;  
• Added Appendix E – Combination Fluvoxamine Maleate and Fluticasone Furoate;  
• Added Appendix F – Montelukast 
(Section 21);  
• Other administrative changes throughout.  
Version 6.0, 17JUN2022 • Appendix B closed to enrollment on 27FEB2022;  
• Removed appendix for combination fluvoxamine maleate and fluticasone furoate ar m;  
• Added Appendix E – Fluvoxamine 
Maleate 100;  
• Added neuropsychiatric events of special interest in Montelukast appendix;  
• Updated the final visit from [ADDRESS_552691]  (footnotes 
added throug hout for Day 120);  
• Other administrative changes throughout.  
Version 7.0, 08DEC2022 • Added C -SSRS collection to the 
Fluvoxamine Maleate 100 Appendix on 
Day 7 and Day 14 and included in the Schedule of Events  (Section  8.1.2, 20.5, 
and Table 1);  
• Changed the Final Visit to Day 180 for participants  consented to protocol v7.0 
(Section 3, 5.3.2, 8.1.3, 8.1.4, 9.1.2, 10.6.8, and Table 1);  
• Added PASC Symptom Questionnaire  
(Section 8.1.4, 8.2, and Table 1);   
• Added C -SSRS and PASC as 
abbreviations;  
• Other administrative changes throughout . 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 67 Version 8.0, 19APR2023  • Updated maximum participation duration 
to align with changes made in the 
previous amendment (Section 1.1);  
• Added exclusion of previous or current enrollment in the ACTIV -6 trial (Sections 
1.1 and 5.2);  
• Updated specifics of study endpoints (Section 3);  
• Clarified statistical details (Section 10) and added the number of events require d 
to perform inference (Section 10.6.2);  
• Added closure date of Appendix E – Fluvoxamine Maleate 100 (Section 20);  
• Clarified that the C -SSRS will only be 
done on participants enrolled in the 
fluvoxamine maleate 100 arm on protocol v7.0 or higher (Section 20.5);  
• Excluded ACTIV -[ADDRESS_552692] appendix (Section 21.2);  
• Added details of the additional 
montelukast study drug provider and removed debossing details from the montelukast tablet description (Sections 21.3.1, 21.3.2, and 21.4.1);  
• Added Appendix G – Metformin 
Hydrochloride Immediate- Release 
(Section 22);  
• Other administrative changes throughout.  
Version 9.0, 16JUL2023  • Expanded screening window to 7 days due 
to operational challenges with shippi[INVESTIGATOR_21395] w ithin 2 days (Section 
8.1); 
• Added hypoglycemia reporting at Day 14 for Appendix G only (Section 8.1 and 
8.1.2);  
• Added enrollment closure dates for Appendix D and F;  
• Updated exclusion criteria for Appendix G based on FDA feedback (Section 22.2);  
• Added lactic acidosis and hypoglycemia as ESIs to Appendix G based on FDA 
feedback (Section 22.5); 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 68 • Other administrative changes throughout.  
Version 10.0, 02AUG2023  • Updated exclusion criteria for Appendix G 
based on FDA feedback (Section 22.2).  
Version 11.0, 26DEC2023 • Added secondary objective (Section 3, synopsis)  
• Adjusted main analysis sample size to  
3000 (Section 10.6)  
• Clarified  between  the analyses  for acute 
COVID and PASC (Sections 10.6.4, 22.6) 
Version 12.0, 05JUN 2024 • Added Post -acute disease objectives and 
endpoints (Section 3) that are specific to 
Appendix G, with corresponding statistical language to the main protocol  
(Section  9) and the metformin appendix 
(Section 21.7)  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 69 14. References  
1. COVID-19 Map FAQ . 2020  [cited 2020; Available from: 
https://coronavirus.jhu.edu/map-faq.html . 
2. McIntosh, K. Coronavirus disease 2019. 2020  [cited 2020 March 24]. 
3. Beigel, J.H., et al., Remdesivir for the Treatment of Covid -19 — Final Report.  New 
England Journal of Medicine, 2020. 383(19): p. 1813-1826. 
4. Dexamethasone in Hospi[INVESTIGATOR_61013] -19 — Preliminary Report.  New 
England Journal of Medicine, 2020. 
5. Gordon, A.C., et al., Interleukin -6 Receptor Antagonists in Critically Ill Patients with 
Covid-19 – Preliminary report.  medRxiv, 2021: p. 2021.01.07.21249390. 
6. Baden, L.R., et al., Efficacy and Safety of the mRNA-1273 SARS-CoV -2 Vaccine.  New 
England Journal of Medicine, 2020. 384(5): p. 403-416. 
7. Polack, F.P., et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New 
England Journal of Medicine, 2020. 383(27): p. 2603-2615. 
8. Voysey, M., et al., Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) 
against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, 
South Africa, and the [LOCATION_006]. The Lancet, 2021. 397([ZIP_CODE]): p. 99-111. 
9. Wang, Z., et al., mRNA vaccine-elicited antibodies to SARS -CoV-2 and circulating 
variants. bioRxiv, 2021: p. 2021.01.15.426911. 
10. Grein, J., et al., Compassionate Use of Remdesivir for Patients with Severe Covid -19. 
New England Journal of Medicine, 2020. 382(24): p. 2327-2336. 
11. Beigel, J.H., et al., Remdesivir for the Treatment of Covid -19 — Preliminary Report.  New 
England Journal of Medicine, 2020. 
12. Wyatt, M.A., et al., Implementation of the “Pregnancy Reasonably Excluded Guide” for Pregnancy Assessment: A Quality Initiative in Outpatient Gynecologic Surgery.  
Obstetrics & Gynecology, 2018. 132(5): p. 1222-1228. 
13. Print, W.H.O.R.D.B. Novel Coronavirus COVID -19 Therapeutic Trial Synopsis . 2020. 
14. Cabrera Martimbianco, A.L., et al., Frequency, signs and symptoms, and criteria adopted 
for long COVID-19: A systematic review.  Int J Clin Pract, 2021. 75(10): p. e14357. 
15. Huang, C., et al., 6-month conse quences of COVID -19 in patients discharged from 
hospi[INVESTIGATOR_307]: a cohort study. The Lancet, 2021. 397([ZIP_CODE]): p. 220-232. 
16. Hirschtick, J.L., et al., Population-Based Estimates of Post -acute Sequelae of Severe 
Acute Respi[INVESTIGATOR_7531] 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics. Clin Infect Dis, 2021. 73(11): p. 2055-2064. 
17. Bell, M.L., et al., Post -acute sequelae of COVID-19 in a non-hospi[INVESTIGATOR_400764]: Results 
from the Arizona CoVHORT. PLOS ONE, 2021. 16(8): p. e0254347. 
18. Davis, H.E., et al., Characterizing long COVID in an international cohort: [ADDRESS_552693]. eClinicalMedicine, 2021. 38. 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 70 19. Cella, D., et al., The Patient -Reported Outcomes Measurement Information System 
(PROMIS): progress of an NIH Roadmap cooperative group during its first two years. 
Med Care, 2007. 45([ADDRESS_552694] 1): p. S3 -S11.  
20. Hays, R.D., et al., PROMIS(®)-29 v2.0 profile physical and mental health summary scores.  Quality of life research : an international journal of quality of  life aspects of 
treatment, care and rehabilitation, 2018. 27 (7): p. 1885 -1891.  
21. Whitehead, J., Sample size calculations for ordered categorical data.  Stat Med, 1993. 
12(24): p. [ADDRESS_552695] 1 (Suppl 1): p. S4 -S4. 
23. Makenga Bof, J.C., et al., Onchocerciasis control in the Democratic Republic of Congo  
(DRC): challenges in a post -war environment. Trop Med Int Health, 2015. 20(1): p. 48-
62. 
24. Chandler, R.E., Serious Neurological Adverse Events after Ivermectin -Do They Occur 
beyond the Indication of Onchocerciasis? Am J Trop Med Hyg, 2018. 98(2): p. 382 -388. 
25. Barkwell, R. and S. Shields, Deaths associated with ivermectin treatment of scabies.  
Lancet, 1997. 349(9059): p. 1144 -5. 
26. MERCK & CO., I. TABLETS STROMECTOL (R) (IVERMECTIN) Product Label . 2009  
[cited 2021 February 12]; Available from: file:/ //U:/Personal/My%20Documents/Medical%20Writing/COVID/ACTIV -
6/Study%20Drugs/Ivermectin.pdf.  
27. Nicolas, P., et al., Safety of oral ivermectin during pregnancy: a systematic review and meta -analysis. The Lancet Global Health, 2020. 8(1): p. e92- e100.  
28. Pacqué, M., et al., Pregnancy outcome after inadvertent ivermectin treatment during 
community -based distribution. The Lancet, 1990. 336(8729): p. 1486 -1489.  
29. Addiss, D.G., et al., Randomised placebo- controlled comparison of ivermectin and 
albendazole alon e and in combination for <em>Wuchereria bancrofti</em> 
microfilaraemia in Haitian children.  The Lancet, 1997. 350(9076): p. 480 -484. 
30. Dreyer, G., et al., Treatment of bancroftian filariasis in Recife, Brazil: a two -year 
comparative study of the efficacy of single treatments with ivermectin or diethylcarbamazine. Trans R Soc Trop Med Hyg, 1995. 89(1): p. 98 -102. 
31. Heukelbach, J., S. Franck, and H. Feldmeier, Therapy of tungiasis: a double -blinded 
randomized controlled trial with oral ivermectin.  Mem Ins t Oswaldo Cruz, 2004. 99 (8): 
p. 873- 6. 
32. Martin -Prevel, Y., et al., Tolerance and efficacy of single high -dose ivermectin for the 
treatment of loiasis.  Am J Trop Med Hyg, 1993. 48(2): p. 186 -92. 
33. Smit, M.R., et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co -
administered with dihydroartemisinin -pi[INVESTIGATOR_436327] -6 Protocol [v12.0] 
 
 71 malaria (IVERMAL): a randomised, double -blind, placebo- controlled trial.  Lancet Infect 
Dis, 2018. 18(6): p. 615 -626. 
34. LLC, E.P., Ivermectin Tablets USP, 7mg, 14mg Investigator's Brochure . 2021.  
35. Yang, S.N.Y., et al., The broad spectrum antiviral ivermectin targets the host nuclear 
transport importin α/β1 heterodimer. Antiviral Res, 2020. 177 : p. 104760.  
36. Caly, L., et al., The FDA-approved drug ivermectin inhibits the replication of SARS -CoV -
2 in vitro.  Antiviral Research, 2020. 178: p. 104787. 
37. Lehrer, S. and P.H. Rheinstein, Ivermectin Docks to the SARS -CoV -2 Spi[INVESTIGATOR_400780] -
binding Domain Attached to ACE2. In Vivo, 2020. 34(5): p. 3023 -3026.  
38. Guzzo, C.A., et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.  Journal of clinical pharmacology, 2002. 42(10): p. 
1122- 1133.  
39. Chaccour, C., et al., Ivermectin and COVID -19: Keepi[INVESTIGATOR_88511]. Am 
J Trop Med Hyg, 2020. 102(6): p. 1156 -1157. 
40. Arshad, U., et al., Prioritization of Anti -SARS -Cov -2 Drug Repurposing Opportunities 
Based on Plasma and Target Site Concentrations D erived from their Established Human 
Pharmacokinetics.  Clin Pharmacol Ther, 2020. 108(4): p. 775 -790. 
41. Bray, M., et al., Ivermectin and COVID -19: A report in Antiviral Research, widespread 
interest, an FDA warning, two letters to the editor and the autho rs' responses.  Antiviral 
research, 2020. 178: p. 104805- 104805.  
42. Zhang, X., et al., Ivermectin inhibits LPS -induced production of inflammatory cytokines 
and improves LPS-induced survival in mice.  Inflamm Res, 2008. 57(11): p. [ADDRESS_552696].  
Fundam Clin Pharmacol, 2009. 23(4): p. 449- 55. 
44. DiNicolantonio, J.J., J. Barroso-Arranda, and M. McCarty, Ivermectin may be a clinically useful anti -inflammatory agent for late-stage COVID -19. Open Heart, 2020. 7(2): p. 
e001350. 
45. Ahmed, S., et al., A five-day course of ivermectin for the treatment of COVID -[ADDRESS_552697] Dis, 2021. 103 : p. 214 -216. 
46. Chachar, A.Z.K., et al., Effectiveness of Ivermectin in SARS -CoV -2/COVID -19 Patients. 
International Journal of Sciences, 2021.  
47. Abu Taiub Mohammed Mohiuddin, C., et al., A Randomized Trial of Ivermectin -
Doxycycline and Hydroxychloroquine -Azithromycin therapy on COVID19 patients. 
Research Square, 2021.  
48. Soto-Becerra, P., et al., Real -World Effectiveness of Hydroxychloroquine, Azithromycin, 
and Ivermectin Among Hospi[INVESTIGATOR_60992] -19 Patients: Results of a Tar get Trial 
Emulation Using Observational Data from a Nationwide Healthcare System in Peru. SSRN Electronic Journal, 2020.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 72 49. Hashim, H.A., et al., Controlled randomized clinical trial on using Ivermectin with 
Doxycycline for treating COVID -19 patients in Baghdad, Iraq. medRxiv, 2020: p. 
2020.10.26.20219345. 
50. Khan, M.S.I., et al., Ivermectin Treatment May Improve the Prognosis of Patients With 
COVID-19. Arch Bronconeumol, 2020. 56(12): p. 828-830. 
51. Morgenstern, J., et al., The use of compassionate Iver mectin in the management of 
symptomatic outpatients and hospi[INVESTIGATOR_88512]-[ADDRESS_552698] 10, 2020. medRxiv, 2020: p. 2020.10.29.20222505. 
52. Krolewiecki, A., et al., Antiviral Effect of High -Dose Ivermectin in Adults with COVID -
19: A Pi[INVESTIGATOR_88513], Controlled, Open Label, Multicentre Trial . 2020, SSRN. 
53. Podder, C.S., et al., Outcome of ivermectin treated m ild to moderate COVID-19 cases: a 
single-centre, open -label, randomised controlled study. IMC Journal of Medical Science, 
2020. 14(2). 
54. Ravikirti, et al., Ivermectin as a potential treatment for mild to moderate COVID -19 – A 
double blind randomized placebo-controlled trial.  medRxiv, 2021: p. 
2021.01.05.21249310. 
55. Morteza Shakhsi, N., et al., Research Square, 2021. 
56. Espi[INVESTIGATOR_54604]-Hernandez, G., et al., Effects of Ivermectin -azithromycin -cholecalciferol 
combined therapy on COVID-19 infected patients: A proof of concept study.  Biomedical 
Research, 2020. 
57. Babalola, O., et al., Ivermectin shows clinical benefits in mild to moderate COVID19: A 
randomised controlled double blind dose response study in Lagos. medRxiv, 2021: p. 2021.01.05.21249131. 
58. NIH. COV ID-19 Treatment Guidelines Fluvoxamine. 2021  [cited 2021 April 23]; 
Available from: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/fluvoxamine/
. 
59. Apotex, Higlights of Fluvoxamine Maleate Tablets Prescribing Information . 
60. Lenze, E.J., et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID -19: A Randomized Clinical Trial. JAMA, 2020. 324(22): p. 
2292-2300. 
61. Rosen, D.A., et al., Modulation of the sigma-1 receptor –IRE1 pathway is beneficial in 
preclinical models of inflammation and sepsis. Science Translational Medicine, 2019. 11(478): p. eaau5266. 
62. Rafiee, L., V. Hajhashemi, and S.H. Javanmar d, Fluvoxamine inhibits some inflammatory 
genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci, 2016. 19(9): p. 977-984. 
63. Seftel, D. and D.R. Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of 
Coronavirus Disease 19. Open Forum Infectious Diseases, 2021. 8(2). 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 73 64. GlaxoSmithKline, Highlights of Prescribing Information for Arnuity Ellipta . 2018: 
Online.  
65. Yamaya, M., et al., Inhibitory effects of glycopyrronium, formoterol, and budesonide on 
coronavirus HCoV -229E replication and cytokine production by [CONTACT_88566][INVESTIGATOR_1663].  Respir Investig, 2020. 58(3): p. 155 -168. 
66. Peters, M.C., et al., COVID -19-related Genes  in Sputum Cells in Asthma. Relationship to 
Demographic Features and Corticosteroids. Am J Respir Crit Care Med, 2020. 202 (1): p. 
83-90. 
67. Finney, L.J., et al., Inhaled corticosteroids downregulate the SARS-CoV -2 receptor ACE2 
in COPD through suppression of type I interferon.  J Allergy Clin Immunol, 2021. 147(2): 
p. 510- 519.e5.  
68. Kern, C., et al., Modeling of SARS-CoV -2 Treatment Effects for Informed Drug 
Repurposing. Front Pharmacol, 2021. 12: p. 625678. 
69. Krolewiecki, A., et al., Antiviral effect of  high-dose ivermectin in adults with COVID -19: 
A proof -of-concept randomized trial. EClinicalMedicine, 2021. 37.  
70. Navarro, M., et al., Safety of high -dose ivermectin: a systematic review and meta -
analysis. J Antimicrob Chemother, 2020. 75(4): p. 827 -834. 
71. Smit, M.R., et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co -
administered with dihydroartemisinin -pi[INVESTIGATOR_88509] (IVERMAL): a randomised, double -blind, placebo- controlled trial.  The Lancet 
Infectious Diseases, 2018. 18(6): p. [ADDRESS_552699] of early treatment with fluvoxamine on risk of emergency care and hospi[INVESTIGATOR_436328] -19: the TOGETHER randomised, platform 
clinical trial.  The Lancet Glo bal Health, 2022. 10(1): p. e42- e51. 
73. Barré, J., J.- M. Sabatier, and C. Annweiler, Montelukast Drug May Improve COVID -19 
Prognosis: A Review of Evidence.  Frontiers in Pharmacology, 2020. 11(1344).  
74. Copertino, D.C., et al., Montelukast drug activity and potential against severe acute 
respi[INVESTIGATOR_6507] 2 (SARS-CoV -2). J Med Virol, 2021. 93(1): p. 187-
189. 
75. Sanghai, N. and G.K. Tranmer, Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COV ID-19 symptoms. Drug Discov Today, 
2020. 25(12): p. [ADDRESS_552700] in pulmonary and 
extrapulmonary manifestations of Covid-19: The enigmatic entity.  Eur J Pharmacol, 
2021. 904 : p. 174196.  
77. Mao, L., et al., Neurologic Manifestations of Hospi[INVESTIGATOR_358843] 2019 in Wuhan, China. JAMA Neurology, 2020. 77(6): p. 683 -690. 
78. Marschallinger, J., et al., Structural and functional rejuvenation of the aged brain by [CONTACT_436365] -asthmatic drug. Nat Commun, 2015. 6 : p. 8466.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552701] in hospi[INVESTIGATOR_436329] -19. The 
Journal of asthma : official journal of the Association for the Care of Asthma, 2021: p. 1-
7. 
80. Kerget , B., et al., Effect of montelukast therapy on clinical course, pulmonary function, 
and mortality in patients with COVID -19. J Med Virol, 2022. 94(5): p. 1950 -1958.  
81. Inzucchi, S.E., et al., Metformin in patients with type 2 diabetes and kidney disease: a 
systematic review.  Jama, 2014. 312(24): p. 2668- 75. 
82. Salpeter, S.R., et al., Risk of fatal and nonfatal lactic acidosis with metformin use in type 
[ADDRESS_552702] Rev, 2010. 2010(4): p. Cd002967.  
83. Eurich, D.T., et al., Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail, 2013. 6(3): p. 395 -402. 
84. Ponikowski, P., et al., 2016 ESC Guide lines for the diagnosis and treatment of acute and 
chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Fail ure Association (HFA) of the ESC.  Eur Heart J, 
2016. 37(27): p. 2129 -2200.  
85. Chang, L.L., G.E. Umpi[INVESTIGATOR_124012], and S.E. Inzucchi, Management of Hyperglycemia in Hospi[INVESTIGATOR_057], Non-Critically Ill Adults.  N Engl J Med, 2022. 387(11): p. [ADDRESS_552703] Worse Outcomes than Patients Treated with Oral Agents.  World J Surg, 2016. 40(7): p. 1575- 82. 
87. Pasquel, F.J. and G.E. Umpi[INVESTIGATOR_124012], Web Exclusive. Anna ls for Hospi[INVESTIGATOR_436330] 
- How We Treat Hyperglycemia in the Hospi[INVESTIGATOR_307].  Ann Intern Med, 2021. 174(8): p. Ho2 -
ho4. 
88. Reitz, K.M., et al., Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes.  JAMA Surg, 2020. 155(6): p. 
e200416. 
89. Brand, K.M.G., et al., Metformin in pregnancy and risk of adverse long-term outcomes: a register -based cohort study. BMJ Open Diabetes Res Care, 2022. 10(1).  
90. Hosey, C.M., K. Halpin, and Y. Yan, Conside ring metformin as a second-line treatment 
for children and adolescents with prediabetes. Journal of Pediatric Endocrinology and Metabolism, 2022. 35(6): p. 727- 732. 
91. Hyer, S., J. Balani, and H. Shehata, Metformin in Pregnancy: Mechanisms and Clinical Applications.  Int J Mol Sci, 2018. 19(7).  
92. Kalafat, E., et al., Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta -analysis of 
randomized trials. Ultrasound Obstet Gyne col, 2018. 52(6): p. 706 -714. 
93. Masarwa, R., et al., Efficacy and Safety of Metformin for Obesity: A Systematic Review.  
Pediatrics, 2021. 147(3). 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 75 94. Warnakulasuriya, L.S., et al., Metformin in the Management of Childhood Obesity: A 
Randomized Control Tr ial. Child Obes, 2018. 14(8): p. 553-565. 
95. Prevention;, C.f.D.C.a. Alcohol and Public Health 2022 April 19, 2022 [cited [ADDRESS_552704] 25]; Available from: 
https://www.cdc.gov/alcohol/faqs.htm#:~:text=What%20does%20moderate%20drinking
%20mean,women%2C%20when%20alcohol%20is%20consumed . 
96. Chen, X., et al., Immunomodulatory and Antiviral Activity of Metformin and Its Potential 
Implications in Treating Coronavirus Disease 2019 and Lung Injury. Front Immunol, 
2020. 11 : p. 2056. 
97. Ventura-López, C., et al., Treatment with metformin glycinate reduces SARS -CoV-2 viral 
load: An in vitro model and randomized, double-blind, Phase IIb clinical trial. Biomed 
Pharmacother, 2022. 152: p. 113223. 
98. Buse, J.B., et al., The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, 
Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.  Diabetes Care, 2016. 39(2): p. 198-205. 
99. Henry, R.R., et al., Improved glycemic control with minimal systemic metformin 
exposure: Effects of Metformin Delayed -Release (Metformin DR) targeting the lower 
bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.  PLoS One, 
2018. 13(9): p. e0203946. 
100. Bramante, C.T., et al., Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for 
Covid-19. New England Journal of Medicine, 2022. 387(7): p. 599-610. 
   
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 76 15. Appendix A (Enrollment Closed 04FEB2022) – Ivermectin [ADDRESS_552705] commonly reported adverse events for ivermectin are pruritus (25.3%), headache 
(13.9%), and dizziness (7.5%) (ICH working group, 2003). Since the 1980s, the use of 
ivermectin in human s for the treatment of filariasis, especially onchocerciasis, has been 
associated with SAEs, including coma, seizure and death only when administered in regions 
where onchocerciasis  and loiasis  are co -endemic.[22]  
The issue of SAEs due to ivermectin is a threat to adherence to mass drug administration and the 
control and elimination of disease in communities co -endemic with  O. volvulus  and Loa. Mass 
drug administration  were suspended from 2004 to 2006 in some health zones in the Equateur, 
Bas Congo, and Oriental provinces in the D emocratic R epublic of the Congo because of 
ivermectin -associated SAEs in the Bas Congo and Oriental p rovinces in 2003.[23] It has been 
thought that c o-infection with L. loa is a risk factor for the development of these reactions. [24] 
Additionally, a study investigating escalating high doses of ivermectin in healthy adults was 
performed to explore the safety of its use in the treatment of head lice. The authors documented 
no evidence of Central Nervous System ( CNS ) toxicity in doses up  to [ADDRESS_552706] FDA -
approved dose of 200 µg/kg.[25]  
Table 3 shows safety events that occurred in greater than 5% of the clinical trial population who received ≥  300 µ g/kg of ivermectin .[26]  For a detailed list of the adverse reactions that occurred 
during clinical trials with ivermectin, refer to the product label  and the Investigator’s Brochure . 
Ivermectin is pregnancy category C and is not contraindicated per FDA. Analyses of outcomes 
of pregnancies in women inadvertently exposed to i vermectin through mass administration 
campaigns show no evidence of increased birth defects, neonatal deaths, maternal morbidity, 
preterm births, or low birthweight over baseline rates. [27, 28]  
Table 3: Ivermectin Adverse Event Table  for Doses ≥  300 µ g/kg 
Indication (dose)  
Wuchererua bancrofti  
(200-400 µg/kg) [29]  
Wuchererua bancrofti  
(200 µg/kg, then 400 
µg/kg on day 4)  [30]  
Stage II or III tungiasis 
lesions (300 µg/kg, 
days 1 & 2)  [31]  
Loa loa  infection (300 
or 400 µg/kg)  [32]  
Symptomatic 
Plasmodium 
falciparum  malaria 
(600 µg/kg)  [33]  
Adverse Reaction s 
Abdominal Pain    7%   
Cough  42%     
Diarrhea     6.5%   
Eye disorders      9% 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 77 Fever  69% 46%  8%  
Gastrointestinal   18%    
Headache  75%  11% 16%  
Local Inflammation   9%    
Local Pain   9%    
Lumber myalgia     6.5%   
Malaise   27%    
Myalgia  37%     
Neurological   15%    
Pneumonia      9% 
Pruritus     60%  
Renal   33%    
Respi[INVESTIGATOR_696]   33%    
15.2. Additional Appendix -Level Exclusion Criteria  
1. End- stage renal disease on renal replacement therapy  
2. Liver failure  or decompensated cirrhosis  
3. Current or planned use of the following drugs during the study, listed by [CONTACT_156276]:  
a. Antiarrhythmic/antihypertensive drug class: quinidine, amiodarone, diltiazem, 
spi[INVESTIGATOR_8407], verapamil  
b. Antibiotic- macrolides drug class: clarithromycin, erythromycin  
c. Antifungal drug class: itraconazole, ketoconazole 
d. Immunosuppressant drug class: cyclosporine, t acrolimus  
e. Anti-HIV drug class: indinavir, ritonavir  
4. Nursing mothers  
5. Pregnancy*   
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods include any of the following: abstinence, partner vasectomy, bilateral tub al ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
15.2.1. Precautions  
While rare, post -marketing reports indicate an increased International Normalized Ratio (INR) 
when ivermectin was co -administered with warfarin. With a 3 -day dosing period this is unlikely 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552707]- spectrum, anti -parasitic agents isolated from Streptomyces avermitilis  
fermentation products. It binds selectively, and with high affinity, to glutamate- gated chloride 
ion cha nnels, therefore increasing cell membrane permeability to chloride ions resulting in death 
of the parasite. [34] It is curre ntly FDA -approved for the following indications: st rongyloidiasis 
of the intestinal tract due to the nematode parasite Strongyloides stercoralis  and onchocerciasis 
due to the nematode parasite Onchocerca volvulus .[26] Per the FDA -approved labelling of 
ivermectin, the recommended dose is 200 µg/kg/day to treat strongyloidiasis  and 150 µg/kg/day 
to treat onchocerciasis in the form of a 3 mg tablet.    
15.3.1. Formulation, Appearance, Packaging, and Labeling 
Ivermectin is a white to yellowish -white, nonhygroscopic, crystalline powder. For this study, 
ivermectin will be supplied as fifteen 7- mg tablets in a bottle with a single panel label . The 
tablets are white, round, biconvex tablets with “123” over the scoring on one side. All packaging 
will be labeled to indicate that the product is for investigational use.  
15.3.2. Drug Dispensing, Storage, and Stability 
Ivermectin will be supplied as [ADDRESS_552708] be stored at temperatures below 30 °C. 
15.3.3. Dosing and Administration  
Ivermectin should be taken on an empty stomach with water  (30 minutes before a meal or 2 
hours after a meal). Each participant will receive a bottle of fifteen  7-mg tablets and will be 
instructed to take a pre- specified number of tablets for 3 consecutive days based on their weight 
(see Table 4) for a daily dose of approximately 300 -400 µg/kg . 
Table 4: Ivermectin 400 Dosing Schedule  
Weight (kg)  Day 1 (# of 7 -
mg tablets)  Day 2 (# of 7 -
mg tablets)  Day 3 (# of 7 -
mg tablets)  Daily Dose  
(µg/kg)  
35-52 2 2 2 269-400 
53-69 3 3 3 304-396 
70-89 4 4 4 315-400 
> 90 5 5 5 ≤ 389 
15.3.4. Rationale for Selection of Dose  
Pre-clinical studies:  
Reports from in vitro  studies suggest that ivermectin acts against ribonucleic acid ( RNA ) viruses 
such as SARS -CoV -[ADDRESS_552709] importin α/β -mediated nuclear transport that prevent 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552710] cell fun ction.[35] A single dose a ddition of 
ivermectin to Vero -hSLAM cells [ADDRESS_552711] a 
5000- fold reduction in viral RNA at 48 hours  and may interfere with the att achment of SARS -
CoV -2 spi[INVESTIGATOR_436331]. [36, 37]  
Ivermectin has been shown to inhibit the replication of SARS -CoV -[ADDRESS_552712] that ivermectin doses up to 100 -fold 
higher than those approved for use in humans would be required to achieve the plasma 
concentrations necessary to duplicate the drug’s antiviral efficacy in vitro .[38, 39] Even though 
ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, 
predicted systemic plasma an d lung tissue concentrations are much lower than 2 µM, the half -
maximal inhibitory concentration (IC 50) against SARS -CoV -2 in vitro .[40, 41] 
Ivermectin demonstrates potential anti -inflammatory properties in some in vitro  
studies,  properties which have been postulated to be beneficial in the treatment of COVID -
19.[42- 44] The dose range for an anti -inflammatory effect may be lower than for the anti -viral 
effects. [44]   
Clinical studies:  
A number of retrospective cohort studies and the results of several randomized trials of ivermectin use in patients with COVID -[ADDRESS_552713] been published in peer- reviewed journals or 
made available as preliminary, non -peer-reviewed reports. Some clinical studies showed no 
benefits after ivermectin use,
 whereas others  reported shorter time to resolution of disease 
manifestations attributed to COVID -19, greater reduction in inflammatory markers,  shorter time 
to viral clearance,  or lower mortality rates in patients who received ivermectin than in patients 
who received co mparator drugs or placebo.[45- 50] 
Most of the studies reported to date are limited by [CONTACT_436366] e, varying dosing 
schedules and the adjunctive use of various concomitant medications  (e.g., doxycycline, 
hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true 
efficacy or safety of ivermectin.  Clinical studies in out patients with COVID -[ADDRESS_552714] clinical trials of outpa tients with 
mild/moderate COVID -[ADDRESS_552715] shown cli nical improvement with even a single dose or a short 
two to five -day cours e of ivermectin given orally shortly after symptom onset. [39, 49, 51, 52]  
There is a dose- dependent relationship between i vermectin dos e and clinical efficacy. Trials 
using lower doses of i vermectin  tend to show no or mi nimal clinical benefit in COVID -19 
patients treated in the outpatient or hospi[INVESTIGATOR_6885]. [53, 54] Higher doses, at least 0.4  mg/kg, 
particularly when administered in multiple doses , have been shown to significantly redu ce time 
to recovery and mortality as compared with lower  doses or placebo/standard care .[51, 55- 57] 
There is a concentration -dependent virologic response seen using hig her-than-usual doses of 
ivermectin (600 μg/kg vs 200 μg/kg once daily for 5 days) that  have been shown to significantly 
reduce the time to PCR viral positivity over standard doses with minimal associated 
toxicities. [52]  
The safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin was tested 
in healthy adult subjects .[38] Doses from 30 mg/day (347-571 µ g/kg) to 120 mg/day  (1404-2000 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 80 µg/kg)  given for 3 days were all well tolerated .[38] These data coupled with evidence of superior 
clinical efficacy of doses i n the lower of this range provide the rationale for the 300 -400 µ g/kg 
dose given for 3 days in the proposed trial. 
15.4. Placebo Information  
15.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo will match the appearance of  the 7-mg ivermectin tablets: white, round, biconvex tablets 
with “123” over the scoring  on one side . A total of fifteen  tablets will be provided in a  bottle  
with a single panel label . The placebo formulation includes the following ingredients in a 210 mg 
tablet: microcrystalline cellu lose, NF (MC -102; pregelatinized s tarch, NF  (Starch 1500); 
croscarmellose s odium, NF  (Vivasol, GF Grade) ; colloidal silicon d ioxide, NF  (Aerosil 200) and 
magnesium s tearate, NF (2257). All packaging will be labeled to indicate that the product is for 
inves tigational use.  
15.4.2. Drug Dispensing, Storage, and Stability 
Placebo must be stored at temperatures below 30°C.  
15.4.3. Dosing and Administration  
Dosing and administration will occur according to Section 16.3.[ADDRESS_552716]  
None  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 81 16. Appendix B (Enrollment Closed 27MAY 2022) – Fluvoxamine M aleate  
16.1. Risk Assessment  
The most common adverse effects of fluvoxamine described in the setting of  treatment of 
psychiatric conditions include gastrointestinal effects, neurological effects, dermatological 
reactions, and in rare cases suicidal ideation. [58] In two 10 -week controlled trials in Obsessive 
Compulsive Disorder (OCD) and depression at doses ranging from 100 -300 mg/day, the most 
commonly observed adverse reactions associated with the use of fluvoxamine maleate tablets (incidence of 5% or greater and at least twice that for placebo) were nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, 
and vomiting  (see Table 5).[59]   
Table  6 lists the complete set of adverse events identified in a randomized clinical trial of 
fluvoxamine (300 mg/day for 15 days) versus placebo in 152 COVID -19 participants. [60] 
Adverse events and serious adverse events were more common in the placebo arm and the single 
SAE in the fluvoxamine arm was dehydration and the study medication was not interrupted.[60]  
Table 5. Fluvoxamine Adverse events occurr ing in 10 -week studies of adult OCD or 
depression  
 *Table shows events that  occurred in ≥ 5% of adult OCD and depression study  
participants receiving 100 -300 mg/day for 10 weeks of fluvoxamine maleate versus 
placebo. [59] 
Adverse Reaction  Fluvoxamine, 
n=892 (%) Placebo, 
n=778 (%) 
Headache  22 20 
Asthenia  14 6 
Nausea  40 14 
Diarrhea  11 7 
Constipation  10 8 
Dyspepsia  10 5 
Anorexia  6 2 
Vomiting  5 2 
Somnolence  22 8 
Insomnia  21 10 
Dry Mouth  14 10 
Nervousness  12 5 
Dizziness  11 6 
Tremor  5 1 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 82 Anxiety  5 3 
 
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants 
receiving 300 mg/day for 15 days. 
Adverse Reaction  [60] 
 Fluvoxamine, n=80 
(%) Placebo, n=72 
(%) 
Pneumonia  3.[ADDRESS_552717] pain or tightness  0 2.8 
Fever  0 2.8 
Acute respi[INVESTIGATOR_1399]  0 1.4 
Serious adverse events  1.3 6.9 
Other adverse events  13.8 8.3 
16.2. Additional Appendix -Level Exclusion Criteria  
1. Use of selective serotonin  (or norepi[INVESTIGATOR_238]) reuptake inhibitors (SSRIs/SNRIs), 
including fluvoxamine, or monoamine oxidase inhibitors (MAOIs) within 2 
weeks of consent including triptans and tryptophan. Use of fluoxetine within 45 days of consent.  
2. Co-administration of tizanidine, thioridazine, alosetron, pi[INVESTIGATOR_3924], diazepam, 
ramelteon, linezolid  
3. Bipolar Disorder 
4. Nursing mothers 
5. Pregnancy* 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 83 *Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods include any of the following: abstinenc e, partner vasectomy, bilateral tubal ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
16.2.1. Precaution s 
Fluvoxamine is a potent inhibitor of CYP1A2 and 2C19 and a moderate inhibitor of CYP2C9, 2D6, and 3A4, as such, it may enhance anticoagulant effects of antiplatelets and anticoagulants 
as well as other medications. It is recommended that concomitant medications listed below be discussed with participants and potential effects of increased drug ex posure reviewed and 
monitored by [CONTACT_4538]/or their prescribing clinician.  
• Tricyclic antidepressants: monitor for side effects with amitriptyline, clomipramine, 
imipramine  
• Antipsychotic drugs: neuroleptic malignant syndrome or similar; particular ly 
clozapi[INVESTIGATOR_050] (hypotension, seizure) 
• Benzodiazepi[INVESTIGATOR_1651]: particularly alprazolam; recommend dose reduction  
• Tramadol, buspi[INVESTIGATOR_5331], fentanyl, lithium, amphetamines, St. John’s Wart , 
carbamazepi[INVESTIGATOR_050], quinidine, and tacrine  
• Methadone: opi[INVESTIGATOR_9845]  
• Mexiletine: monitor for side effects  
• Theophylline: recommend dose reduction and monitor for side effects  
• Warfarin: monitor INR  
• NSAIDS or aspi[INVESTIGATOR_248]: monitor for signs of bleeding  
• Diltiazem, propranolol, metoprolol: monitor for bradycardia  
Participants should be warned ab out fluvoxamine inhibition of caffeine metabolism. A 
description is 1 cup of coffee has the effects of 4 cups  while taking fluvoxamine.  
Caution should be used in participants with hepatic dysfunction due to approximately 30% increase in exposures .  
16.3. Fluvox amine  Information  
Fluvoxamine is an FDA -approved SSRI for the treatment of OCD. Clinically it is also used for 
other conditions such as depression.[58] The active ingredient in fluvoxamine is fluvoxamine 
maleate.  
16.3.1. Formulation, Appearance, Packaging, and Labeling  
Fluvoxamine is a round golden 50 mg tablet that is scored on both sides -  one side has “APO” 
and the other side has “F50” with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 84 16.3.2. Drug Dispe nsing, Storage, and Stability 
Drug will be supplied by [CONTACT_88570]. Study drug should be 
stored in controlled room temperature (20 °C to 25°C); excursions are permitted to 15 °C to 30°C. 
16.3.3. Dosing and Administration  
Fluvoxamine will be self -administered orally by [CONTACT_88571] a dose of 50 mg BID for 10 
days.  
16.3.4. Rationale for Selection of Dose  
The recommended starting dose of fluvoxamine for OCD in adults is 50 mg daily dose to be titrated up to a maximum of 300 mg/day divided  into BID doses. Clinical data from the placebo -
controlled, randomized trial in nonhospi[INVESTIGATOR_88515] -19 demonstrated that a 
50 mg BID fluvoxamine dose was well -tolerated and effective (see Figure 5).[60] In the same 
study, doses of 100 mg BID in COVID -19 participants resulted in additional side effects  over a 
14-day period. The 300 mg daily dose i s for serotonin receptor activity, whereas the postulated 
dose for sigma -1 receptor activity as an anti -inflammatory is lower.  Therefore, the proposed 
dosing regimen of 50 mg BID for 10 days will use the anticipated minimal effective dose to maximize efficacy and minimize toxicity.  
Pre-Clinical Studies : 
Pre-clinical studies have indicated that the anti -inflammatory effects of fluvoxamine may support 
its use for treating COVID -19. Systemic inflammation as a result of infection can damage 
vasculature which may lead to tissue hypoperfusion and multiple organ failure. [61] Reducing 
systemic inflammation thereby  [CONTACT_436367]. In murine studies, administration of fluvoxamine significantly increased survival of 
S1R wildtype (WT) mice and S1R knockout (KO) mice chal lenged with ligand 
lipopolysaccharide (LPS) as compared to mice that received saline ( Figure 4).[61] Fluvoxamine 
also reduced production of inflammatory cytokines in ex vivo  and in vitro  murine and human 
cells (HEK293mTLR4/MD2/CD14, primary lung fibroblasts, and mouse bone marrow -derived 
macrophages) and inflammatory genes in human endothelial cells. [61, 62] 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 85  
Figure 4: Survival curve of WT and S1R KO mice  
Figure note: Mice were treated with vehicle (33% Kolliphor in saline) or STF (30 mg/kg) after 
administration of LPS (2 mg/kg) as indicated in (B) (n = 15 to 16 mice per group; **P < 0.01, ***P < 0.001, log-rank test).[61] 
Clinical Studies : 
A placebo -controlled, randomized trial in nonhospi[INVESTIGATOR_436332] -19 tested the 
efficacy and safety of fluvoxamine (50 mg oral one-time dose, followed by 100 mg orally twice 
daily for 2 days, followed by 100 mg orally three times daily through day 15) versus placebo  
[60]. Results of the study reported that 8.3% (6/72) of participants who received placebo 
experienced clinical deterioration within 15 days of randomization, as opposed to 0% (0/80) in 
the fluvoxamine arm (absolute difference 8.7%; 95% CI, 1.8% to 16.5%;  P = 0.009) .[60]  
Clinical deterioration was  defined as shortness of breath/pneumonia with hypoxia ( Figure 5). 
Concomitant SSRI/SNRI dosing was not allowed per the trial protocol thus the participant’s SSRI/SNRI was held for the study dosing period if reported at baseline.  

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 86  
Figure 5: Summary of JAMA Randomization Clinical Trial of  Fluvoxamine for Early 
COVID-19.  
A prospective, nonrandomized observational cohort study that evaluated fluvoxamine showed 
that on Day 14, 0/65 participants had persistent symptoms as opposed to 19/48 participants who did not receive fluvoxamine (P < 0.001) [63]. Additionally, by [CONTACT_2006] 14, none of the participants who received fluvoxamine were hospi[INVESTIGATOR_88516] 6 participants who were hospi[INVESTIGATOR_88517] (see Figure 6). In this study, all participants were offered fluvoxamine and decided whether or not to take the study drug. Participants who chose to receive the study drug received 50 mg of fluvoxamine two  times a day following an upfront 100 
mg loading dose.[63]  
 
Figure 6: Summary of study results for the prospective, nonrandomized observational 
cohort study with fluvoxamine in participants diagnosed with COVID -19.  

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 87 16.4. Placebo Information  
The placebo will be a fluvoxamine- matched placebo containing mannitol, magnesium stearate, 
hydroxyethyl cellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and purified 
water . The appearance and packaging will match that of the study drug (as described in Section 
17.3.1). All packaging will be labeled to indicate that the product is for investigational use.  
16.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo will match the appearance of the fluvoxamine tablets: round golden 50 mg tablet that is 
scored on both sides -  one side has “APO” and the other side has “F50” with a partial bisect. All 
packaging will be labeled to indicate that the product is for investigational use.  
16.4.2. Drug Dispensing, Storage, and Stability 
Placebo  will be supplied by [CONTACT_88570]. Placebo  should be 
stored in controlled room temperature (20°C to 25°C). 
16.4.3. Dosing and Administration  
Participants  will self -administer  one placebo tablet orally , twice daily for [ADDRESS_552718]  
None  
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 88 17. Appendix C  (Enrollment Closed 08FEB2022) – F luticasone F uroate  
17.1. Risk Assessment  
The most common adverse reactions reported in ≥ 5% of adults  and adolescents  with lung 
disease include nasopharyngitis, bronchitis, upper respi[INVESTIGATOR_1092], and headache. 
Long -term use of systemic and local corticosteroid s may also result in the following side effects: 
Candida albicans  infection, immunosuppression, hypercorticism and adrenal suppression, 
reduction in bone mineral density (BMD), or glaucoma and cataracts. [64] 
There are insufficient data on the use of fluticasone furoate  in pregnant women. There are 
clinical considerations with use of fluticasone furoate  in pregnant women to inform drug-
associ ated risk  and benefit . In animal reproduction studies, fluticasone furoate administered by 
[CONTACT_436368]. The highest fluticasone furoate doses in the rat and rabbit studies were 4 times and 
1 times the maximum recommen ded human daily inhalation dose, respectively. The estimated 
risk of major birth defects and miscarriage for the indicated populations is unknown. In the US general population, the estimated risk of  major birth defects and miscarriage in clinically 
recognized pregnancies is 2% to 4% and 15% to 20%, respectively.[64]  
Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, there is an increased risk of several perinatal outcomes such as pre- eclampsia 
in the mother and prematurity, low birth weight, and small for gestational age in the neonate. [64]  
Table 7. Fluticasone Adverse reactions that occurred in ≥3% of adults and adolescents 
with asthma in a 24-week trial .  
Adverse Reaction  [64]  Fluticasone furoate,  
fluticasone  200 µg, n=119 
(%) Fluticasone furoate, 
fluticasone  100 µg, 
n=119 (%) 
Nasopharyngitis  [ADDRESS_552719] infection  6 2 
Sinusitis  4 7 
Oropharyngeal pain  4 3 
Pharyngitis  3 6 
Back pain  3 3 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 89 Dysphonia  3 2 
Oral candidiasis  3 <1 
Procedural pain  3 <1 
Rhinitis  3 <1 
Throat irritation  3 <1 
Abdominal pain  3 0 
Cough  3 0 
17.2. Additional Appendix -Level Exclusion Criteria  
1. Severe hypersensitivity to milk proteins  
2. Currently prescribed or use within 30 days of inhaled or systemic steroids  
3. Moderate to severe hepatic impairment, defined as Child -Pugh B or C  
4. Nursing mothers  
5. Pregnancy* 
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
17.2.1. Precautions  
While not contraindicated, the following should be considered while taking fluticasone furoate:  
• Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, sa quinavir, 
telithromycin, troleandomycin, voriconazole) should be used with caution as increased systemic corticosteroid adverse effects may occur in combination with fluticasone furoate . Generally, due to the limited study drug administration length, 
clinically significant interactions are unlikely.  
• Paradoxical Bronchospasm may occur with an immediate increase in wheezing after 
dosing. Fluticasone furoate should be discontinued immediately if this occurs.  
17.3. Fluticasone F uroate  Information  
Inhaled fluticaso ne furoate will be provided by [CONTACT_35316]. It is a synthetic trifluorinated 
inhaled corticosteroid ( ICS) with anti -inflammatory activity. In vitro  and in vivo  models have 
shown that fluticasone furoate demonstrates anti -inflammatory actions by [CONTACT_436369], inhibiting pre -inflammatory transcription factors such as 
NFkB, and inhibiting antigen -induced lung eosinophilia, which may contribute to its efficacy in 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 90 the approved indications. It is FDA -approved for once -daily m aintenance treatment of asthma as 
prophylactic therapy in patients 5 years and older. [64]  
17.3.1. Formulation, Appearance, Packaging, and Labeling 
Fluticasone furoate is an inhaled powder drug product. It  is a synthetic trifluorinated 
corticosteroid that is insoluble in water. Fluticasone furoate is a white powder. Fluticasone 
furoate  will be provided in a two tone grey  inhaler with a mouthpi[INVESTIGATOR_436333]. The blister strips us ed for this study will contain a white powder mix with a 
mixture of 200 µg micronized fluticasone furoate and lactose monohydrate. The inhaler will be 
packaged in a moisture- protective foil tray with a desiccant and a peelable lid. [64] All packaging 
will be labeled to indicate that the product is for investi gational use.  
17.3.2. Drug Dispensing, Storage, and Stability 
The study drug should be stored at room temperature (20°C to 25°C) with excursions permitted 
from 15°C to 30°C. It should be stored in a dry environment away from direct heat or sunlight. 
Unopened fluticasone furoate should be stored inside the unopened moisture -protective foil tray 
and only removed immediately before use. Any unused study product should be discarded 6 weeks after opening the foil tray or when the counter reads “0” (after all blisters have been used), whichever comes first. The inhaler is not reusable.[64] The study product has a shelf life of 24 
months when stored at ≤ 25°C. After removal of the secondary package and the desiccant packet 
from the inhaler, the product may be stored up to 6 weeks at ≤ 25°C.  
17.3.3. Dosing and Administration  
Fluticasone furoate is a self -administered inhaled drug. Participants will self -administer 200 µg 
(1 blister) of fluticasone furoate once daily for [ADDRESS_552720] udy drug through the mouthpi[INVESTIGATOR_13959].  
17.3.4. Rationale for Selection of Dose  
Inhaled corticosteroids (ICS) have been shown to be effective in improving asthma and as a combination therapy in chronic obstructive pulmonary disease (COPD) and thus are commonly 
prescribe d medications world- wide. Corticosteroids have been shown to have a broad range of 
pharmacologic activity on multiple cell types including mast cells, eosinophils, neutrophils, 
macrophages and lymphocytes, as well as other mediators of inflammation such as  histamine, 
eicosanoids, and leukotrienes. In addition to the anti -inflammatory role of ICS, there is also 
potential for regulation of gene transcription in epi[INVESTIGATOR_1663]. [65-67] This regulation of gene 
transcription may resu lt in inhibition of SARS -CoV -2 replication. Furthermore, in asthmatic 
patients , ICS may lower gene expression of ACE2 and TMPRSS2. T he ACE2 receptor is 
expressed on epi[INVESTIGATOR_436334] s SARS- CoV -2 for entry and the serine protease TMPRSS2 
primes the SARS -CoV -2 spi[INVESTIGATOR_88520] . Lowering gene expression of ACE2 and 
TMPRSS2 may reduce binding and entry into cells therefore reducing or preventing infection.  
Clinical Studies:  
The PRINCIPLE (Platform Randomized trial of Interventions against COVI D-19 in Older 
People) trial is a multicenter, open -label, multi -arm, adaptive randomized, platform trial. The 
trial is ongoing and released an interim analysis after the Trial Steering Committee advised the 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 91 Trial Management Group that the pre- specified superiority criterion was met on the time to 
recovery in the overall study population and the subgroup of participants with confirmed positive 
SARS -CoV- 2 testing. Participants were eligible if aged >65 years, or > [ADDRESS_552721] 14 days. Participants were randomized to any open active intervention arm including inhaled budesonide and usual care. Participants were followed through an online, dail y symptom diary for 28 days. Participants received usual care plus inhaled 
budesonide 800 µg  daily for 14 days or usual care alone. The primary outcome of the trial at the 
start was hospi[INVESTIGATOR_88521] 28 days; however, the rate of hospi[INVESTIGATOR_436335] a measure of illness duration. The trial was completed with two co -primary endpoints measured within 28 days of randomization: 1) 
time to first reported recovery defined as the first day that a participant reported feeling recovered; and 2) hospi[INVESTIGATOR_88523]-19.  
The interim analysis included eligible SARS -CoV- 2 positive participan ts who were randomized 
to inhaled budesonide (N=751) or usual care alone (N=1028). The mean age was 62.8 years and 83% of participants had co- morbidities. The median days from symptom onset to enrollment was 
[ADDRESS_552722]-recovery in the budesonide arm with an 
estimated median benefit of 3 days. The point estimate of the proportion of COVID -19 related 
hospi[INVESTIGATOR_88524] (8.5%) versus usual care (10.3%), but this did not mee t statistical significance (95% BCI -0.7 – 4.8%). There were two SAE s for 
hospi[INVESTIGATOR_88525]-19, both in the budesonide group.  
A smaller trial of 146 nonhospi[INVESTIGATOR_88515] -19 reported that inhaled 
budesonide at the same do se reduced COVID- 19 related emergency assessments and 
hospi[INVESTIGATOR_059].  
The dose of ICS studied is PRINCIPLE is consistent with a high dose of inhaled steroid. The 
equivalent high dose of fluticasone furoate is 200 µg/day. Inhaled fluticasone furoate has a 
greater anti -inflammatory potency per microgram than budesonide, thus fluticasone furoate is 
administered at a lower daily dose and used only once daily to achieve a similar high dose.  
17.4. Placebo Information  
17.4.1. Formulation, Appearance, Packa ging, and Labeling 
The placebo will be a fluticasone furoate- matched placebo containing lactose for inhalation in 
the same two tone grey  inhaler  that is used for the study drug. The appearance and packaging 
will match that of the study drug (as described in Section 18.3.1). All packaging will be labeled 
to indicate that the product is for investigational use.  
17.4.2. Drug Dispensing, Storage, and Stability 
Placebo will be stored in the same conditions as study drug, ro om temperature (20°C to 25°C) 
with excursions permitted from 15°C to 30°C in a dry environment away from direct heat or sunlight. The placebo has a shelf life of up to 36 months when stored at ≤ 30°C. 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552723]  
None  
17.6. Safety Repor ting for F luticasone F uroate  
Sponsor will promptly notify G laxoSmithKline of all SAEs, UADEs , and pregnancies (if 
applicable), and m edical device deficiencies that have occurred for participants enrolled in this 
Study Drug Appendix, in accordan ce with the timelines and procedures specified in the 
Protocol/appendix. In addition, the sponsor will reasonably obtain and provide follow -up 
information as available, to [COMPANY_004] upon request.  
  
 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 93 18. Appendix D  (Enrollment Closed 22JUL2022) – Ivermectin  600 
18.1. Risk  Assessment  
Refer to Section 16.1.  
18.2. Additional Appendix -Level Exclusion Criteria  
Refer to Section 16.2.  
18.2.1. Precautions  
Refer to Section 16.2.1.  
18.3. Ivermectin  Information  
Refer to Section 16.3.  
18.3.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section 16.3.1.  
18.3.2. Drug Dispensing, Storage, and Stability 
Refer to Section 16.3.2.  
18.3.3. Dosing and Administration  
Ivermecti n should be taken on an empty stomach with water (30 minutes before a meal or 2 
hours after a meal). Each participant will receive a bottle containing the number of 7 -mg tablets 
they require based on their weight and will be instructed to take a pre- specif ied number of tablets 
for 6 consecutive days based on their weight  (see Table 8) for a daily dose of approximately 
400-600 µg/kg.  
Table 8. Ivermectin 600 Dosing Schedule  
Weight 
(kg) Day 1 (# 
of 7- mg 
tablets)  Day 2 (# 
of 7- mg 
tablets)  Day 3 (# 
of 7- mg 
tablets)  Day 4 (# 
of 7- mg 
tablets)  Day 5  (# 
of 7- mg 
tablets)  Day 6  (# 
of 7- mg 
tablets)  Daily Dose 
(µg/kg)  
35-52 3 3 3 3 3 3 403-600 
53-69 4 4 4 4 4 4 406-528 
70-89 6 6 6 6 6 6 470-600 
90-109 7 7 7 7 7 7 450-540 
110-129 8 8 8 8 8 8 434-509 
> 129 10 10 10 10 10 10 < 540 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 94 18.3.4. Rationale for Selection of Dose  
Refer to Section 16.3.4.  
Additional relevant pre-clinical studies : 
Modeling studies have supported high dose a nd longer duration of ivermectin. One modeling 
study reported 600 µ g/kg daily for [ADDRESS_552724]  while 300 µ g/kg for [ADDRESS_552725] efficacy. [68] Following thi s modeling study, a  recent ly published  proof- of-
concept randomized controlled clinical trial in hospi[INVESTIGATOR_436336] 600 µ g/kg 
ivermectin for 5 days, a dose stil l wel l within the range for safety, wa s associated with IC 50 for 
anti-viral activity in vitro  while lower doses (300 µ g/kg) were  not.[69] The anti -viral activity was 
identified in the subgroup of patients on ivermectin with higher mean plasma concentrations. 
When the ivermectin group was further divided into subgroups with 160 ng/mL as the plasma 
concentration cutoff, the median Cmax achieved was 202 ng/mL in those with plasma 
concentration >160 ng/mL and this group had greater reduction in viral load at day 5. These data 
argue for the use of higher dosi ng regimens in clinical trials.  
The safety of higher doses of ivermectin is well understood. At least six published trials have 
administered ivermectin at doses above 400 µ g/kg. [70] These include over 2,500 independent 
administrations of cumulative 800 µ g/kg within one week and over 2,000 single dose 
administrations of 800 µ g/kg. The primary side effect of higher doses, usually due to peak 
concentrations, is transient and mild visual disturbances not found to be structural and found to 
self-resolve. One such study randomized 47 patients with malaria to receive ivermectin 600 
µg/kg daily for 3 days versus 300 µ g/kg daily for 3 days versus placebo.[71] The 600 µ g/kg 
group had more adverse events than the other groups. Treatment -related adverse events exhibited 
a dose -response relationship, with predominantly transient minor visual disturbances  that w ere 
deemed non- severe.  
18.4. Placebo Information  
Refer to Section 16.4.  
18.4.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section 16.4.1.  
18.4.2. Drug Dispensing, Storage, and Stability 
Refer to Section 16.4.2.  
18.4.3. Dosing and Administration  
Dosing and administration will occur according to Section 19.3.[ADDRESS_552726]  
• Photophobia  
• Blurred vision  
• Visual impairment  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 95 19. Appendix E (Enrollment Closed 20JAN 2023) – Fluvoxamine Maleate 100  
19.1. Risk Assessment  
Refer to Section 17.1.  
19.2. Additional Appendix -Level Exclusion Criteria  
Refer to Se ction 17.2.  
19.2.1. Precaution s 
Refer to Section 17.2.1.  
19.3. Fluvoxamine  Information  
Refer to Section  17.3.  
19.3.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section 17.3.1. Fluvoxamine tablets remain 50 mg.  
19.3.2. Drug Dispensing, Storage, and Stability 
Refer to Section 17.3.2.  
19.3.3. Dosing and Administration  
Fluvoxamine will be self -administered orally by [CONTACT_88571] a dose of 50 mg BID for one 
day (first two doses at 50 mg), followed by 100 mg (two 50 mg tablets) BID for 12 days 
(remaining 24 doses at 100 mg), for a total of 13 days (26 doses , 50 tablets ) of fluvoxamine.  
19.3.4. Rationale for Selection of Dose  
Refer to Section  17.3.4.  
Additional relevant rationale : 
The recommended starting dose of fluvoxamine for OCD in adults is 50 mg daily to be titrated 
up to a maximum of 300 mg/day divided into BID doses. The 300 mg d aily dose is for serotonin 
receptor activity, whereas the postulated dose for sigma- 1 receptor activity as an anti -
inflammatory is lower.  The TOGETHER trial is a randomized, placebo -controlled, adaptive 
platform trial that demonstrated a 100 mg BID fluvoxa mine dose  for 10 days  was well -tolerated 
and effective (see  Figure 7) in nonhospi[INVESTIGATOR_88515] -19.[72] This is a 
multicenter study conducted in Brazil. Participants were >  [ADDRESS_552727] one risk factor for severe 
disease. Participants were randomized to active drug versus placebo, and due to the concurrent enrollment into multiple active arms, pooled placebo was used for each active arm. The primary 
outcome was a composite endpoint of medical admission to the hospi[INVESTIGATOR_436337] -19, 
which was defined as more than 6 hours in an emergency care setting (acute care areas set up to 
respond to capacity) or referral for hospi[INVESTIGATOR_11298], within 28 days of randomization. Key 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 96 secondary outcomes included viral clearance, time to clinical improvement, and all -cause 
mortality. The planned accrual, based on an assumption of 15% event rate in the placebo group, 
was 681 participants per a rm.  
The study randomized 741 participants to fluvoxamine and 756 to placebo. In the fluvoxamine group 79 (11%) participants had a primary out come event versus 119 (16%) in the pooled 
placebo arm (relative risk 0.68 [95% Bayesian credible interval, 0.52- .88]). Secondary outcomes 
including viral clearance at day 7, hospi[INVESTIGATOR_059], and mortality were not different between arms. There was no significant difference in the number of treatment -emergent adverse events in the 
two arms. Thus, this large randomized, double -blind, controlled trial is suggestive of safety and 
efficacy of fluvoxamine dosed 100 mg twice daily in people with mild -to-moderate COVID -19.  
 
Figure 7. Probability of efficacy for the primary outcome in the ITT and mITT  populations 
of TOGETHER  
19.4. Placebo Information  
Refer to Section  17.4.  
19.4.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section  17.4.1.  
19.4.2. Drug Dispensing, Storage, and Stability 
Refer to Section  17.4.2.  
19.4.3. Dosing and Administration  
Participants will self -administer one placebo tablet orally BID for one day, followed by [CONTACT_436370] (four total per day) for 12 days, for a tota l of 13 days of placebo 
tablets . 

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552728]  
For participants enrolled in the Fluvoxamine Maleate 100 appendix on protocol v7.0 or later, 
suicidal ideation and behavior will be assessed at Day 7 and Day 14 via the Columbia -Suicide 
Severity R ating Scale (C -SSRS) Screener Since Last Asked Self -Report. The C -SSRS asks a 
total of up to six questions and a minimum of three questions . Sites will follow local policies in 
response to high risk screen cases. In addition, high risk screen cases will be  advised to dial 988 
to access the 988 Suicide & Crisis Lifeline.     
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 98 20. Appendix F (Enrollment Closed 23JUN2023) – Montelukast  
20.1. Risk Assessment  
The most common adverse reactions that occurred at a greater frequency in montelukast than in 
placebo and at an incidence rate ≥5% include upper respi[INVESTIGATOR_4416], fever, headache, 
pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, and otitis.  
Post-market reports of neuropsychiatric events associated with montelukast have included 
agitation, hostility, anxiousness, depression, sleepwalking, suicidal thinking/behavior, and tremors.  
Table 9. Montelukast sodium adverse reactions occurring at a higher incidence than 
placebo, in ≥1% of adults and adolescents ≥ [ADDRESS_552729] sodium  
10 mg/day, n=1955 (%)  Placebo, n=1180 
(%) 
Pain, abdominal  2.9 2.5 
Asthenia/fatigue 1.[ADDRESS_552730] Increase 1.6 1.2 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552731] that inhibits the cysteinyl leukotriene CysLT1 receptor. It 
is indicated for prophylaxis and chronic treatment of asthma, acute prevention of exercise-
induced bronchoconstric tion, relief of seasonal allergic rhinitis, and  relief of  perennial allergic 
rhinitis in patients ≥ [ADDRESS_552732] Healthcare Inc.  or 
Camber Pharmaceuticals  and distributed by [CONTACT_436371]’s International 
Pharmacy . Montelukast tablets should be stored at 25°C with excursi ons permitted from 15°C to 
30°C, protected from moisture and light.  
20.3.3. Dosing and Administration  
Montelukas t will be self -administered orally by [CONTACT_88571] a dose of 10 mg  (1 tablet)  
once daily for 14 days.  
20.3.4. Rationale for Selection of Dose  
Preclinical Studies:  
Montelukast is a potent cysteinyl leukotriene receptor antagonist with anti -inflammatory effects 
and has been proven to significantly suppress oxidative stress and cytokine production. 
Pre-clinical in vitro  studies demonstrate montelukast’s ability to act as an anti -viral agent against 
RNA  viruses such as Zika, Influenza A, and Hepatitis C , among others.[73] A virtual s creening 
tool, using an in silico molecular docking analysis, was used to simulate the binding of 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552733] to catalytically active sites within the SARS‐CoV‐[ADDRESS_552734] the main protease was −105.71, and the RNA dependent 
RNA polymerase was −104.75. These docking scores suggest that montelukast is likely to dock 
to both the main protease and the RNA dependent RNA pol ymerase of SARS‐CoV‐2, therefore 
demonst rating the potential to inhibit  the enzymatic activity of the proteins and subsequently 
disrupting the substrate binding site. [74]   
Montelukast inhibits the signaling of NF -κB, such as interleukin- 6,8,10, TN F-alpha, MCP -1, and 
other proinflammatory mediators, which may result in a corresponding reduction of 
proinflammatory mediators, thereby [CONTACT_436372]. [75] 
Pulmonary and extra -pulmonary manifestations in COVID -[ADDRESS_552735].[76]  
In addition, 36.4% of patients with COVID -19 experience CNS involvement, and although the 
majority of these events include h eadache, anosmia, and dysgeusia;  more serious events such as 
stroke, delirium, and seizures have  been reported.[77] In a 6 -week treatment of young (4 months) 
and old (20 months) rats with montelukast, a reduction of neuroinflammation was seen; elevation of hippocampal neurogenesis and improvement in learning and memory in old animals was seen. 
By [CONTACT_436373], the authors demonstrated that the effect 
was mediated through inhibition of the GPR17 receptor.[78]  
Clinical studies:  
One published retrospective analysis of hospi[INVESTIGATOR_436338] -[ADDRESS_552736] (10 mg orally, once daily, at the discretion of the treating provider) 
included ninety -nine patients not previously on montelukast in the analysis ([ADDRESS_552737]/[ADDRESS_552738]) . Inclusion required hospi[INVESTIGATOR_403403] [ADDRESS_552739] was started 
on day 1 of hospi[INVESTIGATOR_436339] 1 were on hydroxychloroquine. Steroids were used by 16 -23% of patients during the first 3 days of hospi[INVESTIGATOR_5478] 33- 40% of patients 
during the entire hospi[INVESTIGATOR_059]. A univariate logistic regression revealed a lower risk of clinical deterioration in patients who were receiving montelukast, defined as any increase in ordinal scale 
from day 1 to day 3 of hospi[INVESTIGATOR_059], (OR, 0.23; P =.029); however, in a multivariable logistic regression, the results in patients [ADDRESS_552740] was not 
significantly associated with a reduced risk of clinical deterioration (OR, 0.28; P =.058). [79] 
A recent prospective, randomized, controlled, single -blinded, single -center study investigated 
standard of care treatment versus two doses of montelukast (10 mg/day or 20 mg/day) in addition 
to standard of care treatment in hospi[INVESTIGATOR_436340] -19 at the Erzurum 
Regional Training and Research Hospi[INVESTIGATOR_436341].[80] To be considered for enrollment, 
patients were required to have a PaO2/FiO2 ratio above [ADDRESS_552741] of care treatment  (per Turkish Ministry of Health this was favipi[INVESTIGATOR_436342] a total of 5 
days) . The primary outcome was  a composite of  progression to ARDS and/or  macrophage 
activation syndrome (MAS) . MAS was assessed at Day 5 of treatment. Clinical outcomes of 
disease progression were captured during hospi[INVESTIGATOR_059]. Based on an assumption of a 20% or 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 101 greater reduction in the primary outcome, the sample size was determined to be total accrual of 
180 participants enroll ed (60 in each group). The two montelukast arms were combined for the 
clinical outcome analysis. The standard of care arm had more MAS or ARDS events (8 vs 3, p  = 
0.001) and mortality (4 vs 0) than the pooled active treatment arms. There was no adverse event reporting in this manuscript , and there are numerous weaknesses to the study design.  
Although the preclinical montelukast data available for SARS‐CoV‐[ADDRESS_552742] propose a range of 
doses for testing (10 mg orally daily for 28- 60 days; 60 mg orally daily for 14 days), see Table 
10. One completed observational study ([STUDY_ID_REMOVED]5) has not posted study results. The proposed dose  (Section 21.3.3) of [ADDRESS_552743] Trial (COSMO)  Phase 3, randomized, blinded, placebo-
controlled trial with 600 participants  10 mg daily for 60 
days [STUDY_ID_REMOVED] 
Efficacy of 
Montelukast in Mild -
moderate Respi[INVESTIGATOR_436343]- COVID -
19: (E -SPERANZA)  Phase 3, double -blind, 
randomized, placebo -
controlled trial with 284 participants  20 mg daily for 28 
days [STUDY_ID_REMOVED] 
A National, Multi -
Center, Open-Label, 
Three -Arm, Phase II 
Study to Investigate the Effect of Montelukast Between 
Emergency Room 
Visits and Hospi[INVESTIGATOR_436344] -[ADDRESS_552744] Treatment  Phase 2, 3 arm (montelukast, 
montelukast plus 
favicovir, and favicovir), open- label, 
randomized trial with [ADDRESS_552745] arm dosing: 6x10 mg 
montelukast daily for 
14 days  [STUDY_ID_REMOVED] 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552746] sodium.  The final  packaging  of the placebo will match that of the study drug (as 
described in Section 21.3.1).  
20.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo will be tablets with the following  appearance: beige, rounded square -shaped, biconvex, 
film-coated tablets . All packaging will be labeled to indicate that the product is for 
investigational use.  
20.4.2. Drug Dispensing, Storage, and Stability 
Placebo will be supplied by [CONTACT_436374]’s International Pharmacy . Placebo should be stored at controlled room tempe rature 
25°C, excursions permitted from 15°C to 30°C. 
20.4.3. Dosing and Administration  
Participants will self -administer one placebo tablet orally daily for [ADDRESS_552747]  
Neuropsychiatric events including agitation, hostility, anxiousness, depression, sleepwalking, 
suicidal thinking/behavior, and tremors.  
  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 103 21. Appendix G – Metformin Hydrochloride Immediate-R elease   
21.1. Risk Assessment  
The most common adverse reactions (>  5%) with metformin hydrochloride include diarrhea, 
nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache.  
Cholestatic, hepatocellular, and mixed hepatocellular liver  injury have been reported with 
postmarketing use of metformin.  
Safety concerns around metformin have centered around a risk of lactic acidosis, however the  
historical concern was driven by [CONTACT_436375]. Several large studies and 
Cochrane reviews have demonstrated no increased risk of lactic acidosis, and in fact fewer cases 
of lactic acidosis, in persons on metformin  compared to other diabetes treatments .[81, 82] This 
includes in adults with heart failure. [83, 84] Metformin is also safe in adults with kidney disease 
and should not be withheld from persons with glomerular filtration rates >30 m L/min/1.73m2 (or 
lower ) because of associations with improved macrovascular outcomes in persons with chronic 
kidney disease. [81] Guidelines recommend metformi n should no longer be stopped upon hospi[INVESTIGATOR_436345].[85 -88] Metformin’s safety has been demonstrated in children an d 
during lactation and pregnancy.[89 -94] 
21.2. Additional Appendix -Level Exclusion Criteria  
1. Chronic kidney disease including e nd-stage renal disease on renal replacement therapy  
(dialysis)  
2. Chronic liver disease with ascites   
3. History of metabol ic acidosis  and/or current use of bicarbonate supplementation  
4. Current or recent use (within 14 days) of r anolazine, dolutegravir, cimetidine, pacritinib, 
erdafitinib, fexinidazole, patiromer, r isdiplam, t afenoquine , vandetanib, zonisamide, 
acetazolamide, dichlorphenamide  
5. Type 1 diabetes mellitus  or type 2 diabete s mellitus , currently taking insulin or a 
sulfonylurea   
6. Does not a gree to less than moderate alcohol consumption*  during the Intervention 
Period  
* Defined as greater than 2 drinks a day for men and 1 drink a day for women. A drink is 
equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% 
alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a “shot” of 80-
proof (40% alcohol content) distilled spi[INVESTIGATOR_363811] (e.g., gin, rum, vodka, whiskey). [95] 
7. Breastfeeding or planning to breastfeed a premature infant (born at < 37 weeks of 
gestation) or an infant with renal imp airment during the Intervention Period  
8. Currently participating as a study team member in support of the ACTIV -6 trial  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552748] indicated that metformin -associated lactic acidosis could result in 
death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms of lactic acidosis 
include malaise, myalgias, respi[INVESTIGATOR_1506], somnolence, and abdominal pain. Risk factors of 
lactic acidosis include significant renal impairment, concomitant use of carbonic anhy drase 
inhibitors, age > [ADDRESS_552749], surgery and other procedures, 
hypoxic states, excessive alcohol intake, and hepatic impairment. Laboratory abnormalities from 
postmarketing cases included elevated blood lactate levels, anion gap acidosis, increased 
lactate/pyruvate ratio , and metformin plasma levels generally >5 µg/mL. Steps to reduce the risk 
of and manage metformin- associated lactic acidosis in high risk groups are provided in the Full 
Prescribing Information. If l actic acidosis is suspected, study drug will be discontinued.  
Additional precautions include Vitamin B12 Deficiency with long -term use (> 1 year), and 
increased risk of hypoglycemia with concomitant use with insulin and insulin secretagogues.  
Alcohol can  theoretically potentiate the effect of metformin on lactate metabolism, participants 
should be warned to avoid excessive alcohol intake. Drugs such as vandetanib may increase the accumulation of metformin; as such, concomitant use of these drugs is not al lowable in the 
study. Excessive use of alcohol is also not allowable.  
21.3. Study Drug  Information  
Metformin hydrochloride  is a biguanide and is indicated, in combination with diet and exercise, 
to improve glycemic control in adults and pediatric patients 10 y ears of age and older with type 2 
diabetes mellitus. Metformin is an antihyperglycemic hydrochloride that is a white to off -white 
crystalline compound. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves  insulin sensitivity by [CONTACT_436376].  This study will use the immediate release (IR) formulation of metformin.  
21.3.1. Formulation, Appearance, Packaging, and Labeling 
Metformin  IR tablets contain the active metformin hydrochloride and inactive ingredients 
including povidone and magnesium stearate. Commercially  available m etformin [ADDRESS_552750] is for investigational use.  
21.3.2. Drug Dispensing, Storage, and Stability 
Metformin IR will be dispensed in light -resistant containers and  should be  stored at 20° to 25°C 
(68° to 77°F); excursions permitted to 15° –30°C (59°–86°F).  
21.3.3. Dosing and Administration  
Metformin IR tablets will be self -administered orally according to the following dosing schedule:  
• 500 mg on Day 1;  
• 500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and 
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 105 • 500 mg in the morning and 2 x 500 mg  (a total of 1000 mg) in the evening o n Day 6 
through Day 14.  
21.3.4. Rationale for Selection of Dose  
Preclinical data suggests metformin has immunomodulatory activity that reduces the production 
of proinflammatory cytokines while stimulating the formation of neu trophil extracellular traps 
that may directly inhibit SARS -CoV -2.[96, 97] The hypothesis is that the primary mechanism of 
action for metformin against SARS -CoV -2 relies on metformin’s availability in the plasma. The 
systemic exposure of IR metformin is higher than for extended- release (XR) metformin. Anti -
viral medications are also considered more effective when started early in the course of infection, 
and IR  metformin is faster to reach systemic levels above 500 ng/mL.  
While the preclinical data shown  in Figure 8 and Figure 9 use  a dose of 2000 mg per day of IR, 
2000 mg per day is also the dose at which the risk of side effects increases significantly (Figure 9). Rapi[INVESTIGATOR_436346] 2000 mg per day within 2 weeks appeared to increase the risk 
of side effects. The proposed dose of 1500  mg daily balances  the need to achieve a consistent 
dose and an effective dose without causing side effects.  A dose titration is typi[INVESTIGATOR_436347], to avoid side effects and study drug discontinuation.  
Preclinical Studies:  
Preclinical data supports the use of the IR formulation to ach ieve systemic exposure. One study 
with samples from 19 evaluable patients receiving a single dose of metformin demonstrated 
higher plasma metformin levels in those who received IR as opposed to delayed -release [DR] 
(Figure 8). A randomized, phase 2, parallel -group, multicenter, placebo- controlled study of 
double -blind placebo or [ADDRESS_552751] and single -blind metformin IR (2000 mg) 
similarly showed high er systemic metformin plasma levels following dosing of an IR 
formulation as opposed to DR (Figure 9).  
 
Figure 8. Mean (SD) plasma metformin concentrations by [CONTACT_436350] a 
single daily dose of metformin.  
Figure Note: Treatments were administered at  t = 0 h (8:00 p.m.) and at  t = 12 h (8:00 a.m.) 
except for metformin (Met ) XR, which was administered as a single dose at  t = 0 (black arrows). 

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 106 Meals were administered at  t = −0.42, 2.08, 11.5, 18.08, and 24.[ADDRESS_552752] dose 
(dotted vertical lines). [98] 
 
Figure 9. Metformin systemic (plasma) exposure  
Figure Note: (A) observed at trough (median) and (B) steady state AUC 0-24h (geometric mean 
[95% CI ]) estimated from trough and post -dose sampling. Efficacy presented as (C) Hemoglobin 
A1C ( HbA1c ) change at Week 16 (L east squares  mean + standard error) and (D) Average 
concentration  Week 4 –16 change in fasting glucose from baseline (L east S quares  mean + 
standard error). Data are from the mITT p opulation (n = 542), with the exception of modeled 
steady -stated metformin AUC 0-24h (ITT population; n = 571). * p<0.[ADDRESS_552753] -baseline value for HbA1c that was collected no more than 1 week after discontinuing 
study medication and prior to taking a new anti -diabe tic concomitant medication that could 
reasonably be expected to influence subsequent glycemic data. [99] 
Clinical Studies:  
Metformin IR is more widely available and less expensive than XR or DR  metformin. M etformin  
IR is over the counter in some countries, like Brazil and Spain, but XR and DR formulations are 
not.  

CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552754] (750 mg twice daily for 10 
days) to placebo in a total of 418 participants with confirmed SARS -CoV -2 infection, including 
symptoms within 7 days of Screening and one additional hi gh-risk criterion. The results showed 
no difference in the primary outcome of hospi[INVESTIGATOR_26109] > [ADDRESS_552755] and placebo. Additionally, no clinical improvement 
(according to the World Health O rganization clinical worsening scale) was identified at 28 
days. [72]  The TOGETHER Trial did not have a dose titration, and starting at 1,[ADDRESS_552756] a benefit for metformin. In the per -protocol analysis, 4.76% (8 of 168) in the metformin 
group versus 7.82% (14 of 179) of controls were hospi[INVESTIGATOR_057].  
Another trial performed in Mexico compared metformin IR (620 mg twice daily for 14 days) to 
placebo in a total of 20 participants with type 2 diabetes mellitus who presented with severe 
acute respi[INVESTIGATOR_436348] -CoV -2 infection. The results showed a 
significant reduction in the viral load of those who re ceived metformin IR (93.2%) as opposed to 
those on placebo (78.3%) and lower supplemental oxygen intake on days 2, 5, and 7 in those who received metformin IR (5.9 points) versus those on placebo (10.6 points).[97]  
One trial of metformin IR for outpatient treatment of COVID -19 has been completed in the US , 
COVID -OUT . Metformin IR prevented over 40% of emergency department visits, 
hospi[INVESTIGATOR_602], and death due to COVID -19 (OR 0.58, 95% CI, 0.35 to 0.94) by [CONTACT_2006] 14. By 
[CONTACT_2006] 28, those in the metformin  IR group were also less likely to be hospi[INVESTIGATOR_057], 1.34% (8/596) 
versus 3.16% (19/601) of those receiving placebo. Treatm ent with metformin IR during acute 
COVID -19 infection prevented over 40% of Long COVID cases, with 6.3% of participants in the 
metformin IR group and 10.6% in the placebo group receiving a diagnosis of Long COVID from a medical provider. [100]  
21.4. Placebo Information  
21.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo tablets will be provided by  [CONTACT_436377]. 
One bot tle of [ADDRESS_552757] is for investigational use.  
21.4.2. Drug Dispensing, Storage,  and Stability 
Placebo will be stored in the same conditions as study drug, room temperature (20°C to 25°C) 
with excursions permitted from 15°C to 30°C in a light -resistant container.  
21.4.3. Dosing and Administration  
Participants will self -administer placebo acco rding to the following schedule:  
• One (1) placebo tablet on Day 1;  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 108 • One (1) placebo tablet in the morning and 1 placebo tablet in the evening o n Day 2 
through Day 5; and 
• One (1) placebo tablet in the morning and [ADDRESS_552758]  
• Lactic acidosis will be reported as an ESI if the event is reported during a hospi[INVESTIGATOR_059]  
• Occurrence of hypoglycemia will be recorded on Day [ADDRESS_552759] -acute disease (Appendix G only) is that participants who receive 
metformin will have lower risk of PASCD at day 180 compared to those who receive placebo. The d ay 180 endpoint (PASCD) is applicable for participants who were consented to the study 
after protocol v7.0 was implemented . 
21.7.2. Sample Size Considerations  
From 1 January 2022 to 31 December 2022, ACTIV -6 enrolled 4498 patients, of whom 3751 
patients responded to day 90 surveys (83.4% response rate). Of those responding, 262 reported persistent symptoms at 90 days. As it currently stands, ACTIV -6 is powered at about 80% to 
detect a reduction in risk from 7% to 3.5% (a 50% relative risk reduction; required sample size 
for 80% power is 1272). Under more conservative assumptions of a 40% relative risk reduction 
from 6% to 3.6% among responders only, 2488 participants would be needed. If the rate of 
symptom persistence is lower, say 5%, slightly larger sample sizes would be required. A halv ing 
of risk from 5% to 2.5% would require 1812 participants for 80% power, and a 40% relative risk reduction to 3% would require 3012 participants. W e will therefore increase accrual for the main 
analysis to ~3 000.  
CONFIDENTIAL  ACTIV -6 Protocol [v12.0] 
 
 [ADDRESS_552760] passed day 180 under the 
assumption of accrual to n= 3000. The SAP will address the influence of interim analyses on 
Type 1 error as appropriate.  
21.7.3. Interim Analysis 
i) Secondary Objective IA (n=600 passing Day 90): A  futility analysis on the PASC 
endpoint will be conducted when [ADDRESS_552761] passed day 90 under the 
assumption of accrual to n=3000.  
 